Calcium receptor antagonists

专利摘要:
Formula [Ⅰ] [Wherein, R 1 is an aryl group which may be substituted or the like; R 2 is a C 1-6 alkyl group which may be substituted or the like; R 3 is a hydrogen atom or the like; R 4 is a hydrogen atom or the like; R 5 and R 6 are each a C 1-6 alkyl group or the like; R 7 is an aryl group which may be substituted, or the like; X 1 , X 2 , X 3 are each a C 1-6 alkylene group or the like; X 4 and X 5 are each a single bond or the like], a salt thereof or a solvate thereof or a prodrug thereof; Pharmaceutical compositions containing these compounds, salts, solvates or prodrugs (including calcium receptor antagonists); And intermediates of these compounds, salts, solvates or prodrugs.
公开号:KR20030059100A
申请号:KR10-2003-7002012
申请日:2001-08-10
公开日:2003-07-07
发明作者:시나가와유꼬；가쯔시마다께오；나까가와다까시
申请人:니뽄 다바코 산교 가부시키가이샤；
IPC主号:

专利说明:

Calcium Receptor Antagonist {CALCIUM RECEPTOR ANTAGONISTS}
[2] The calcium receptor senses extracellular Ca ²⁺ concentrations to raise intracellular Ca ²⁺ , thereby acting to inhibit the production of parathyroid hormone (PTH), which is involved in Ca ²⁺ metabolism regulation and bone metabolism regulation.
[3] The serum calcium concentration in normal mammals is strictly maintained at about 9-10 mg / 100 ml (about 2.5 mM), which is called calcium homeostasis of living organisms. When this value falls below 50%, it causes rigidity. On the contrary, when the value rises by 50%, it causes clouding of consciousness, which leads to a life threatening condition. Maintenance of calcium homeostasis, the duodenum is the absorption body of Ca ^2+, Bone is a storage organ of Ca ^2+, and also each serving as a Ca ²⁺ excretory organ of the kidney. In addition, such control of Ca ²⁺ dynamics is performed by various hormones collectively referred to as "calcium regulating hormone". Representative hormones include active vitamin D [1α, 25 (OH) ₂ D ₃ ], PTH, calcitonin, parathyroid hormone-related protein (PTH-related protein: PTHrP), and the like.
[4] The bone plays an important role not only as a supportive tissue of the living body and as an exercise organ, but also as a storage organ of its component Ca ²⁺ . To achieve this function, bone tissue repeats its formation (bone formation) and absorption (bone absorption) for life. Osteoblasts derived from mesenchymal cells play a major role in bone formation, and osteoclasts derived from hematopoietic cells play a major role in bone resorption. Osteogenesis is a mechanism that undergoes the formation of analogous bone by bone matrix (eg, bone matrix proteins such as collagen type I) produced by osteoblasts present on the surface of bone formation and subsequent coalification. On the other hand, bone resorption is a mechanism in which osteoclasts adhere to the bone surface, absorb Ca ²⁺ intracellularly through acid secretion and ion transport, and release Ca ²⁺ into the bone marrow to release Ca ²⁺ into the blood. Defects of bone absorbed by osteoclasts are repaired by bone formation by osteoblasts. Such a series of phenomena is called bone remodeling, and by remodeling, old bone is replaced with new bone, thereby maintaining the strength of the whole bone and maintaining calcium homeostasis.
[5] PTH is a hormone that plays a central role in the maintenance of calcium homeostasis. When blood Ca ²⁺ levels decrease, the secretion of PTH from the parathyroid gland is immediately promoted, and bone acts on osteoblasts (activation of osteoclasts by osteoblasts, production of osteoorganolytic enzymes, etc.) to promote osteoclast bone resorption. Ca ²⁺ is recruited from the bone to the blood. In addition, PTH promotes the resorption of Ca ^{2+ in} the distal tubules in the kidney and activates 25 (OH) vitamin D ₃ in the proximal tubules to promote Ca ²⁺ uptake from the intestine. Promotes the production of type vitamin D ₃ [1α, 25 (OH) ₂ D ₃ ]. It also suppresses reabsorption of phosphorus. As described above, PTH directly or indirectly has a function of raising blood Ca ²⁺ concentration.
[6] On the other hand, when the concentration of Ca ^{2+ in the} blood rises, the calcium receptor detects it and immediately inhibits the secretion of PTH from the parathyroid gland, thereby reducing the amount of Ca ²⁺ supplied to the blood [Brown, EM, Homeostatic mechanisms regulating extracellular and intracellular calcium metabolism, in the parathyroids, p. 19, (1994), Raven press, New York]. The secretion of PTH is also inhibited by the active vitamin D ₃ [1α, 25 (OH) ₂ D ₃ ].
[7] Since PTH is a hormone that plays an important role in the regulation of Ca ²⁺ metabolism and bone metabolism, attempts are being made to apply PTH to the treatment of osteoporosis. In 1982, Tham et al. Reported that continuous administration of bovine PTH (1-84) to thyroid / parathyroid-extracted rats increased both bone formation and bone resorption of the cavernous bones of the femur, resulting in a decrease in net bone mass. It was found that hyperactivity of bone resorption was not seen, only bone formation was increased and bone mass was increased. Endocrinology, 110 , 506-512 (1982). Uzawa et al. Also compared the effects of continuous and intermittent administration of PTH in the incisors of the long bone and interphapal cavernous bones of young rats. As a result of continuous administration of PTH, bone mass was remarkably increased in the interosseous endothelial cancellous bone, which had a great influence on intrachondral osteochondralization, but the bone mass was remarkably increased. Has been significantly enhanced and bone mass has been reduced with cortical bone porosity [Bone, 16 , 477-484 (1995)]. It has also been reported that in the case of intermittent administration of PTH, bone mass and bone marrow increased significantly in both distal and distal cortical bones without increasing osteoclasts or decreasing cortical bone.
[8] In addition, Skirt et al. Reported that short-time (10-20 minutes) treatment of PTH promotes cell proliferation in chicken osteoblast-derived osteoblasts compared to long-term (18 hours) treatment [Calcif. Tissue Int., 55 , 208-215 (1994)]. In view of this, some of the actions of PTH on osteoblasts are transient, and the phenomenon that these actions are expressed by very short treatments is related to the different effects on bone tissue in sustained and intermittent administration of PTH in vivo. You can think of it as possible.
[9] In addition, Ishitsuya et al. Examined the effect of PTH on the differentiation of osteoblasts using an in vitro laboratory system, and revealed that the action of PTH depends on the treatment time. When PTH was continuously acted on the cranial tube-derived osteoblasts of the first cultured rats, they strongly inhibited the differentiation of osteoblasts and almost completely inhibited the formation of bone in vitro, but the first 6 hours at 48 cycles Repeating the action of PTH alone has been reported to significantly promote differentiation of osteoblasts and to promote bone formation in vitro.
[10] In addition, PTH not only prevents bone loss in the osteoporosis model, but is also believed to have a bone mineral recovery effect on animals in which bone loss has already occurred significantly. Lonsky et al. Intermittently administered human PTH (1-34) for 15 weeks from 4 weeks after ovarian extraction, using SD rats 90 days old, which clearly reduced the spongy bone during 4 weeks after ovarian extraction. As a result, hyperstimulation of bone formation and suppression of bone resorption were observed from 5 weeks to 10 weeks after the start of administration, indicating that bone volume was increased by about 2 times that of the surgeon group [Endocrinology, 132 , 823-831 (1993) ]. They also reported that estrogens and bisphosphonates prevent bone loss due to ovarian extraction, but no bone mass increase such as PTH is observed. In addition, they analyzed the cortical bones of this experimental system in detail, and the bone formation promoting phase and bone mass increase were observed on the periosteal side and the endothelium side by human PTH (1-34) intermittent administration. It was also not accompanied by a decrease in cortical bone [Bone, 15 , 51-58 (1994)].
[11] Moseskill et al. Also described spongy bones of rat vertebral bone [Endocrinology, 129 , 421-428 (1991)] or cortical bones by intermittent administration of human PTH (1-34) or human PTH (1-84). Bone Miner. Res., 8 , 1097-1101 (1993), reported that not only bone mass increases, but also compressive and bending strength, which are indicators of bone quality, increase in dose-dependent manner. Although there is an effect, various studies have been carried out on the constraints that are assumed in actual clinical applications. Mizo Gucci examined the pharmacological effects of PTH intermittent administration even when blood PTH, which is presumed to be one of the causes of osteoporosis, was observed and observed to increase bone mass as usual. [Journal of Japanese Society of Bone Morphometry, vol. 5, pp. 33-39 (1995). In addition, Dakao et al. Reviewed the interval of administration of PTH, and reported that the dose of bone was increased in dose-dependently with little increase of bone resorption even once a week for 12 weeks in normal rats. [Japanese Journal of Bone Metabolism , vol. 12 (Suppl.), P. S343 (1994), suggesting that clinically useful low frequency administration is likely to be effective. These results suggest that PTH could be a potent and promising drug for treating postmenopausal osteoporosis or ovarian exfoliation osteoporosis, which can increase bone mass and decrease fracture rate.
[12] It is clear from these results that the treatment of osteoporosis will be possible by intermittent administration of PTH. However, in the case of PTH, injection must be employed as a means of administration, leaving many patients with pain. On the other hand, orally administrable drugs which can raise blood PTH concentration intermittently are expected as a therapeutic agent for osteoporosis by a novel mechanism of action different from the PTH and conventional calcitonin.
[13] Calcium receptors, however, are G protein conjugated receptors that penetrate the cell membrane seven times, cloned as essential molecules for PTH secretion. The human calcium receptor consists of 1078 amino acids, indicating 93% amino acid homology with the bovine calcium receptor. The human calcium receptor is composed of a large N single extracellular region consisting of 612 amino acids, a cell transmembrane region consisting of 250 amino acids, and a C terminal intracellular region consisting of 216 amino acids.
[14] In addition to the parathyroid gland, calcium receptors are also expressed in kidneys, thyroid C cells, brain, and the like, and bone marrow cells have also been identified.
[15] When the calcium receptor binds to ligands such as Ca ²⁺ , it conjugates with G protein to activate phospholipase C, induce the production of inositol triphosphate, increase the intracellular Ca ²⁺ concentration, and as a result, secrete PTH. Is suppressed [Nature, 366 , 575-580 (1993)].
[16] As described above, drugs that inhibit the activation of calcium receptors, that is, drugs that antagonize calcium receptors, release inhibition of PTH secretion in parathyroid cells and promote PTH secretion. At this time, if the antagonism can increase the blood concentration of PTH non-persistently and intermittently, the same effect as that of the intermittent administration of PTH to the antagonist can be expected, and a very effective drug can be obtained for the treatment of osteoporosis. It is thought to be.
[17] CaSR antagonists describe compounds represented by the following formula in WO 99/51569 and pharmaceutically acceptable salts and complexes thereof.
[18]
[19] [Wherein, Y ₁ is an alkylene or alkenylene having 4 or more carbon atoms substituted with a covalent bond, unsubstituted or C _1-4 alkyl, or O;
[20] Y ₂ is methylene unsubstituted or substituted with C _1-4 alkyl or haloalkyl;
[21] Y ₃ is a covalent bond or O, S, NR ^IV or C _1-4 alkylene-O, C _1-4 alkylene-S, C _1-4 alkylene-NR ^IV ;
[22] R ₃ and R ₄ are independently methyl or ethyl, or unite to form cyclopropyl;
[23] R ₅ is aryl or condensed aryl, dihydro or tetrahydro condensed aryl,
[24] These are unsubstituted or OH, halogen, C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, OSO ₂ R ^IV , CN, NO ₂ , OCF ₃ , CF ₃ , CH ₂ CF ₃ , (CH ₂ ) _n CO ₂ R ^IV and O- (CH ₂ ) _n CO ₂ R ^IV substituted with any one of the substituents selected from the group, where n is an integer of 0 to 3, R ^IV is H, C _1-4 alkyl and C _3-6 cycloalkyl;
[25] Or R ₅ is heteroaryl or condensed heteroaryl; Wherein the heterocycle contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or OH, OCH ₃ , CH (CH ₃ ) ₂ , halogen, C _1-4 alkyl, C _1-4 alkoxy , C _3-6 cycloalkyl, OSO ₂ R ^IV , CN, NO ₂ , OCF ₃ , CF ₃ , CH ₂ CF ₃ , (CH ₂ ) _n CO ₂ H, (CH ₂ ) _n CO ₂ R ^IV and O- (CH ₂ ) _n CO ₂ R ^IV is substituted with any one selected from the group consisting of;
[26] G is a covalent bond, CHR ₆ or CR ₆ , wherein R ₆ is H, OH or O (forms a ketone);
[27] R ₇ is H, OH or OC _1-4 alkyl;
[28] R ₈ is H or C _1-4 alkyl; Or R ₇ and R ₈ are integrated to form a ketone; A and B are independently selected from the group consisting of a bond, CH ₂ , NH, O, S and C═O, provided that either A or B is selected from CH ₂ and NH; Or A and B are integrally combined; Or CH = CH or C≡C at the AB site;
[29] X ₁ and X ₅ are independently selected from the group consisting of H, halogen, CN, NO ₂ , C _1-4 alkyl, cycloalkyl, CH ₂ -aryl and CH ₂ -heteroaryl; Provided that either X ₁ or X ₅ is H;
[30] X ₂ , X ₃ and X ₄ are H, halogen, OC _1-4 alkyl, O-aryl, O-heteroaryl, CH ₂ -aryl, and CH ₂ -heteroaryl, alkyl, C (O) aryl, C ( O) heteroarylCH (OH) aryl, CH (OH) heteroaryl and JK;
[31] J is a covalent bond, alkylene, O-alkylene or alkenylene of at least 5 carbon atoms, which are unsubstituted or C _1-4 alkyl, OH, O (forms a ketone), aryl, heteroaryl and NR'R " Substituted with a substituent selected from the group consisting of wherein R 'and R "are independently a group consisting of H, alkyl, aryl, heteroaryl, C (O) alkyl, C (O) aryl and C (O) heteroaryl Is selected from;
[32] K is selected from the group consisting of CO ₂ R ^IV , OH and CN.
[33] In particular Y ₃ is C _1-4 alkylene-O
[34]
[35] Although the compound represented by is not described directly, it is suggested. However, in this case, "C _1-4 alkylene" refers to a straight chain, and the branching like the present invention is not described and is not suggested.
[36] WO 99/51241 also describes compounds represented by the following formula as CaSR antagonists, and pharmaceutically acceptable salts and complexes thereof.
[37]
[38] [Wherein, Y ₁ is an alkylene or alkenylene having 4 or more carbon atoms which is covalently bonded, unsubstituted or substituted with C _1-4 alkyl or O;
[39] Y ₂ is methylene unsubstituted or substituted with C _1-4 alkyl or haloalkyl;
[40] Y ₃ is selected from the group consisting of covalent bonds or O, S, NR ^IV , C _1-4 alkylene-O, C _1-4 alkylene-S and C _1-4 alkylene-NR ^IV ;
[41] R ^IV is selected from the group consisting of H, C _1-4 alkyl and C _3-6 cycloalkyl;
[42] R ₃ and R ₄ are independently methyl or ethyl, or unite to form cyclopropyl;
[43] R ₅ is heteroaryl or condensed heteroaryl; Wherein the heterocycle contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or OH, OCH ₃ , CH (CH ₃ ) ₂ , halogen, C _1-4 alkyl, C _1-4 alkoxy , C _3-6 cycloalkyl, OS ₂ R ^IV , CN, NO ₂ , OCF ₃ , CF ₃ , CH ₂ CF ₃ , (CH ₂ ) _n CO ₂ H, (CH ₂ ) _n CO ₂ R ^IV and O- (CH ₂ ) _n CO ₂ R ^IV and substituted with any one selected from the group consisting of; n is an integer of 0 to 3;
[44] G is a covalent bond, CHR ₆ or CR ₆ , wherein R ₆ is H, OH or O (forms a ketone);
[45] R ₇ is H, OH or OC _1-4 alkyl;
[46] R ₈ is H or C _1-4 alkyl; Or R ₇ and R ₈ are integrated to form a ketone;
[47] A and B are independently selected from the group consisting of a bond, CH ₂ , NH, O, S and C═O, provided that any one of A and B is selected from CH ₂ and NH; Or A and B are integrally combined; Or CH = CH or C≡C at the AB site;
[48] X is selected from the following subformulae (Ia) to (Ie);
[49]
[50]
[51]
[52]
[53]
[54] Where W is R ₁ , SO ₂ R ₁ , C (O) R ₁ , SO ₂ NR ₁ R ₁ ′, C (O) NR ₁ R ₁ ′, C (O) OR ₁ and SO ₃ R ₁ ′ Wherein R ₁ and R ₁ ′ are independently hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2-5 alkynyl, heterocycloalkyl, Aryl and aryl C _1-4 alkyl; Or R ₁ and R ₁ ′ are combined to form a 3 to 7 membered heterocyclic ring; Wherein any substituent is selected from the group consisting of CN, aryl, CO ₂ R, CO ₂ NHR, OH, OR, NH ₂ , halo, CF ₃ , OCF ₃ and NO ₂ ; R represents C _1-4 alkyl or C _3-6 cycloalkyl;
[55] X ₁ is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R ', OR', CF ₃ , OCF ₃ and OSO ₂ R ', wherein R' is C _1-4 Alkyl or C _3-6 cycloalkyl;
[56] X ₂ , X ₃ and X ₄ are independently selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R ″, OR ″, CF ₃ , OCF ₃ and OSO ₂ R ″, provided that , X ₁ or X ₃ is H, wherein R ″ is C _1-4 alkyl or haloalkyl; Or X ₁ and X ₂ are integrated to form an aryl or heteroaryl ring, which is substituted or unsubstituted; Wherein the heteroatom is selected from N, S and O; And the optional substituent is selected from the group consisting of halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ R ′ and NO ₂ ; Or X ₃ and X ₄ independently represent C (O) R ₁ ; And
[57] R ₂ is selected from the group consisting of hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2-5 alkynyl, heterocycloalkyl, aryl and aryl C _1-4 alkyl ;
[58] X ₁ ″ is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R, OR, CF ₃ , OCF ₃ and OSO ₂ R, wherein R is C _1-4 alkyl or C _3-6 cycloalkyl;
[59] X ₂ ", X ₃ " and X ₄ "are independently selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R ', OR', CF ₃ , OCF ₃ and OSO ₂ R ' Provided that either X ₁ ″ or X ₃ ″ is H, wherein R ′ is C _1-4 alkyl or haloalkyl; or X ₁ ″ and X ₂ ″ are integrated to form an aryl or heteroaryl ring A hetero atom is selected from N, S and O, and any substituent is halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ -C _1-4 alkyl, OSO ₂ -C _3-6 cycloalkyl, and NO ₂ ;
[60] Or X ₃ "and X ₄ " independently represent C (O) R ₁ ; And
[61] R ₁ ″ and R ₂ ″ are independently selected from the group consisting of hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2-5 alkynyl, heterocycloalkyl and aryl ; Or R ₁ "and R ₂ " are united to form a 3 to 7 membered optionally substituted heterocyclic ring; The substituent is selected from any of the group consisting of CN, aryl, CO ₂ R ″, CO ₂ NHR ″, OH, OR ″, NH ₂ , halo, CF ₃ , OCF ₃ and NO ₂ ;
[62] Wherein R ″ represents C _1-4 alkyl or C _3-6 cycloalkyl;
[63] X ₁ "'is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R, OR, CF ₃ , OCF ₃ and OSO ₂ R, wherein R is C _1-4 alkyl or C _3-6 cycloalkyl;
[64] X ₂ "', X ₃ "' and X ₄ "'independently consist of CN, NO ₂ , Cl, F, Br, I, H, R', OR ', CF ₃ , OCF ₃ and OSO ₂ R' Selected from the group, provided that either X ₁ "'or X ₃ "' is H, where R 'is C _1-4 alkyl or haloalkyl;
[65] Or X ₁ "'and X ₂ "' are integrated to form an aryl or heteroaryl ring, which is substituted or unsubstituted; Wherein the heteroatom is selected from N, S and O, and the substituents are halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ -C _1-4 alkyl, OSO ₂ -C _{3- 6} cycloalkyl and NO ₂ ;
[66] Or X ₃ "'and X ₄ "' independently represent C (O) R ₁ ;
[67] R ₁ "'and R ₂ "' are independently hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2-5 alkynyl, heterocycloalkyl and aryl Is selected; R ₁ "'and R ₂ "' are united to form a 3 to 7 membered optionally substituted heterocyclic ring; Wherein any substituent is selected from the group consisting of CN, aryl, CO ₂ R ″, CO ₂ NHR ″, OH, OR ″, NH ₂ , halo, CF ₃ , OCF ₃ and NO ₂ ; wherein R ″ is C _1-4 alkyl or C _3-6 cycloalkyl;
[68] D is selected from the group consisting of H, CN, NO ₂ , Cl, F, Br, I, R, OR, SR, CF ₃ , OCF ₃ and OSO ₂ R, wherein R is C _1-4 alkyl, C _3-6 cycloalkyl or C _1-10 aryl or heteroaryl, the heteroatoms selected from N, S and O, the substituents being halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ -C _1-4 alkyl, OSO ₂ -C _3-6 cycloalkyl and NO ₂ ; n is an integer of 1 or 2;
[69] Each E is independently C or N, provided that at least two E sites are not N; And when n is 2, each E is C;
[70] a and b may represent a bond;
[71] R ₁ ^IV is (CH ₂ ) _n CO ₂ R ′, (CH ₂ ) _n CO ₂ H, (CH ₂ ) _n CONR ' ₂ , (CH ₂ ) _n CH ₂ OR', OR ', SR', CN, NO ₂ , Cl, F, BR, I, H, CF ₃ , OCF ₃ , OSO ₂ R ', R' and H, wherein R 'is C _1-4 alkyl or C _3-6 Cycloalkyl;
[72] Or R ₁ ^IV is O forming a ketone, ie YR ₁ ^IV represents —C═O;
[73] R ₂ ^IV is selected from the group consisting of hydrogen, CN, NO ₂ , Cl, F, Br, I, H, R ″, OR ″, CF ₃ , OCF ₃ and OSO ₂ R ″; wherein R ″ is C _1-4 alkyl or C _3-6 cycloalkyl.
[74] Y is selected from the group consisting of C, CH, O, N and S; With the proviso that when Y is S, then R ₁ ^IV is O or not represented; Provided that when Y is 0, R ₁ ^IV is not represented;
[75] X 'is CH ₂ , NH, O and S.
[76] R ₉ is 0-alkyl, O—CH ₂ -aryl and O-aryl;
[77] X ₁ "" is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R, OR, CF ₃ , OCF ₃ and OSO ₂ R, wherein R is C _1-4 alkyl or C _3-6 cycloalkyl;
[78] X ₂ "", X ₃ "" and X ₄ "" independently consist of CN, NO ₂ , Cl, F, Br, I, H, R ', OR', CF ₃ , OCF ₃ and OSO ₂ R ' Selected from the group, provided that either X ₁ "" or X ₃ "" is H, wherein R 'is C _1-4 alkyl or haloalkyl;
[79] Or X ₁ "" and X ₂ "" are integrated to form an aryl or heteroaryl ring, which is substituted or unsubstituted; Wherein the heteroatom is selected from N, S and O, and the substituents are halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ -C _1-4 alkyl, OSO ₂ -C _{3- 6} cycloalkyl and NO ₂ ;
[80] Or X ₃ "" and X ₄ "" independently represent C (O) R ₁ ].
[81] Here again Y ₃ is C _1-4 alkylene-O
[82]
[83] Although the compound represented by is not described directly, it is suggested. However, also in this case, "C _1-4 alkylene" means a straight chain, and the branch as in the present invention is neither described nor suggested.
[84] International Publication No. WO 98/45255 (EP-A-973730) also describes compounds represented by the following formulae as CaSR antagonists.
[85]
[86] [Wherein, Y ₁ is an alkylene or alkenylene having 4 or more carbon atoms substituted with a covalent bond, unsubstituted or C _1-4 alkyl;
[87] Y ₂ is methylene unsubstituted or substituted with C _1-4 alkyl CF ₃ ;
[88] Z is selected from the group consisting of covalent bonds or O, S, NH, NC _1-4 alkyl, O (CH ₂ ) _n , (CH ₂ ) _n O, NR "'C = O and C = ONR"', Wherein R ″ ′ is C _1-4 alkyl, and n is an integer from 1 to 3,
[89] R ₃ and R ₄ are independently methyl or ethyl, or unite to form cyclopropyl;
[90] R ₅ is phenyl or naphthyl, unsubstituted or OH, C _1-4 alkylCH (CH ₃ ) ₂ , halo, halo C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, OSO ₂ Substituted with one or more substituents selected from the group consisting of R ^IV , CN, NO ₂ , OCF ₃ , CF ₃ and CH ₂ CF ₃ , wherein R ^IV is C _1-4 alkyl or C _3-6 cycloalkyl Represents;
[91] G is a covalent bond or CR ₆ , wherein R ₆ is H, OH or O (which forms a carbonyl moiety);
[92] R ₇ is H, OH or OC _1-4 alkyl;
[93] R ₈ is H or C _1-4 alkyl; Or R ₇ and R ₈ are integrated to form a carbonyl moiety;
[94] AB moiety represents CH ₂ CH ₂ , a covalent bond, —CH═CH— or —C≡C—; And
[95] X is selected from the group consisting of the following subformulae (Ia), (Ib), (Ic), (Id) and (Ie);
[96] Formula Ia
[97]
[98] Formula Ib
[99]
[100] Formula Ic
[101]
[102] Formula Id
[103]
[104] Formula Ie
[105]
[106] In the sub-formula (Ia),
[107] W is a group consisting of R ₁ , SO ₂ R ₁ , C (O) R ₁ , SO ₂ NR ₁ R ₁ ′, C (O) NR ₁ R ₁ ′, and C (O) OR ₁ SO ₃ R ₁ ′ Wherein R ₁ and R ₁ ′ are independently hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2-5 alkynyl, heterocycloalkyl, aryl and aryl C _1-4 alkyl is selected from the group consisting of; Or R ₁ and R ₁ ′ are combined to form a 3 to 7 membered heterocyclic ring; Optional substituents here are selected from any of the group consisting of CN, aryl, CO ₂ R, CO ₂ NHR, OH, OR, NH ₂ , halo, CF ₃ , OCF ₃ and NO ₂ ; Wherein R represents C _1-4 alkyl or C _3-6 cycloalkyl;
[108] X ₁ is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R ', OR', CF ₃ , OCF ₃ and OSO ₂ R ', wherein R' is C _1-4 Alkyl or C _3-6 cycloalkyl;
[109] X ₂ , X ₃ and X ₄ are independently selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R ″, OR ″, CF ₃ , OCF ₃ and OSO ₂ R ″, wherein In which R ″ is C _1-4 alkyl or haloalkyl; Or X ₁ and X ₂ are integrated to form an aryl or heteroaryl ring, which is substituted or unsubstituted; Wherein the heteroatom is selected from N, S and O; And the substituent is selected from any of the group consisting of halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ R ′ and NO ₂ ; Or X ₃ and X ₄ independently represent C (O) R ₁ ;
[110] Provided that when there is a polysubstitution from haloalkyl to halo, halo represents F; Or X ₁ or X ₃ is hydrogen; And
[111] R ₂ is selected from the group consisting of hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2-5 alkynyl, heterocycloalkyl, aryl and aryl C _1-4 alkyl ;
[112] In the sub-formula (Ib):
[113] X ₁ ″ is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R, OR, CF ₃ , OCF ₃ and OSO ₂ R, wherein R is C _1-4 alkyl or C _3-6 cycloalkyl;
[114] X ₂ ", X ₃ " and X ₄ "are independently selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R ', OR', CF ₃ , OCF ₃ and OSO ₂ R ' _Wherein R 'is C _1-4 alkyl or haloalkyl, provided that when there is a polysubstitution from haloalkyl to halo, halo represents F, or X ₁ "and X ₂ " are integrated to form aryl or hetero Forms an aryl ring, substituted or unsubstituted, wherein the heteroatom is selected from N, S and O, and any substituent is halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ -C _1-4 alkyl, OSO ₂ -C _3-6 cycloalkyl and NO ₂ ;
[115] Or X ₃ "and X ₄ " independently represent C (O) R ₁ ;
[116] Provided that either X ₁ "or X ₃ " is hydrogen; And
[117] R ₁ ″ and R ₂ ″ are independently selected from the group consisting of hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2-5 alkynyl, heterocycloalkyl and aryl ; Or R ₁ "and R ₂ " are united to form a 3 to 7 membered optionally substituted heterocyclic ring; May further contain a heteroatom selected from O, S and N; Wherein any substituent is selected from any one of the group consisting of CN, aryl, CO ₂ R ″, CO ₂ NHR ″, OH, OR ″, NH ₂ , halo, CF ₃ , OCF ₃ and NO ₂ ; R ″ represents C _1-4 alkyl or C _3-6 cycloalkyl;
[118] In the sub-formula (Ic):
[119] X ₁ "'is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R, OR, CF ₃ , OCF ₃ and OSO ₂ R, wherein R is C _1-4 alkyl or C _3-6 cycloalkyl;
[120] X ₂ "', X ₃ "' and X ₄ "'independently consist of CN, NO ₂ , Cl, F, Br, I, H, R', OR ', CF ₃ , OCF ₃ and OSO ₂ R' Is selected from the group wherein R 'is C _1-4 alkyl or haloalkyl, provided that when there is a polysubstitution of halo in haloalkyl, halo represents F or X ₁ "' and X ₂ "'are integral To form an aryl or heteroaryl ring, which is substituted or unsubstituted, wherein the heteroatom is selected from N, S and O, and the substituents are halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ -C _1-4 alkyl, OSO ₂ -C _3-6 cycloalkyl and NO ₂ ; or X ₃ "'and X ₄ "' independently represent C (O) R ₁ Represents;
[121] Provided that either X ₁ "'or X ₃ "' is H; And
[122] R ₁ "'and R _2"' are independently hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, C _2-5 alkenyl, C _2- 5 alkynyl, heterocycloalkyl from the group consisting of alkyl and aryl Is selected; Or R ₁ "'and R ₂ "' are united to form a heterocyclic ring in which a heteroatom selected from O, S and N may be additionally contained, which may be 3 to 7 membered substituted; Wherein the substituent is selected from the group consisting of CN, aryl, CO ₂ R ″, CO ₂ NHR ″, OH, OR ″, NH ₂ , halo, CF ₃ , OCF ₃ and NO ₂ ; wherein R ″ is C _{1 -4} alkyl or C _3-6 cycloalkyl;
[123] In the sub-formula (Id):
[124] D is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, R, OR, SR, CF ₃ , OCF ₃ and OSO ₂ R, wherein R is C _1-4 alkyl, C _{3- 6} cycloalkyl, or C _1-10 aryl or heteroaryl, wherein the heteroatoms are selected from N, S and O, and the substituents are halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ -C _1-4 alkyl, OSO ₂ -C _3-6 cycloalkyl and NO ₂ ; n is an integer of 1 or 2;
[125] Each E is independently C or N,
[126] Provided that no two or more E moieties are N;
[127] Provided that when n is 2, each E is C;
[128] a and b may represent a bond;
[129] R ₁ ^IV is (CH ₂ ) _n CO ₂ R ′, (CH ₂ ) _n CO ₂ H, (CH ₂ ) _n CONR ' ₂ , (CH ₂ ) _n CO ₂ OR', OR ', SR', CN, NO ₂ , Cl, F, Br, I, CF ₃ , OCF ₃ , OSO ₂ R ′, R ′ and H; Wherein R 'is C _1-4 alkyl or C _3-6 cycloalkyl;
[130] Or R ₁ ^IV is O forming a ketone, ie YR ₁ ^IV represents —C═O;
[131] R ₂ ^IV is selected from the group consisting of hydrogen, CN, NO ₂ , Cl, F, Br, I, H, R ″, OR ″, CF ₃ , OCF ₃ and OSO ₂ R ″; wherein R ″ is C _1-4 alkyl or C _3-6 cycloalkyl.
[132] Y is selected from C, CH, O, N and S; Provided that when Y is S, R ₁ ^IV is O; Provided that when Y is 0, R ₁ ^IV is not represented;
[133] X 'is CH ₂ , NH, O and S; And
[134] The bonding site is a carbon atom described by 3;
[135] In the sub-formula (Ie):
[136] X ₁ "" is selected from the group consisting of CN, NO ₂ , Cl, F, Br, I, H, R ', OR', CF ₃ , OCF ₃ and OSO ₂ R ', wherein R' is C _{1 -4} alkyl or C _3-6 cycloalkyl;
[137] X ₂ "", X ₃ "" and X ₄ "" independently consist of CN, NO ₂ , Cl, F, Br, I, H, R ", OR", CF ₃ , OCF ₃ and OSO ₂ R " Is selected from the group wherein R ″ is C _1-4 alkyl or haloalkyl; Or X ₁ "" and X ₂ "" are integrated to form an aryl or heteroaryl ring, which is substituted or unsubstituted; Wherein the heteroatom is selected from N, S and O; And either substituent is selected from the group consisting of halo, C _1-4 alkyl, OCF ₃ , CF ₃ , OMe, CN, OSO ₂ R ′ and NO ₂ ; Or X ₃ "" and X ₄ "" independently represent C (O) R ₁ ;
[138] Provided that when there is a polysubstitution of halo in haloalkyl, halo represents F; And either X ₁ "" or X ₃ "" is hydrogen;
[139] And R ₉ is O-CH ₂ -alkyl, O-CH ₂ -aryl and O-aryl]
[140] Japanese Unexamined Patent Publication No. 2001-501584 (WO97 / 37967, EP-A-901459, USP 6022894) also describes compounds represented by the following formulae as CaSR antagonists.
[141]
[142] [[In the formula, R ₁ is selected from the group consisting of aryl, long chain alk and cyclo alk;
[143] R ₂ is lower alk, cyclo alk, alkoxy, H, OH, = O, C (O) OH, C (O) O-lower alk, C (O) NH-lower alk, C (O) N (lower alk ) ₂ , SH, S-lower alk, NH ₂ , NH-lower alk and N (lower alk) ₂ ; R ₃ and R ₄ are each independently lower alk or collectively cyclopropyl;
[144] R ₅ is optionally substituted naphthyl or optionally lower having 1 to 4 substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br and lower haloalkoxy Substituted phenyl having 1 to 4 substituents having at least one substituent in the meta or para position, selected from the group consisting of alkyl, methoxy, Cl, F, Br and lower haloalkoxy, provided that the substituted phenyl is 2 And may have 3 additional substituents;
[145] R ₆ , when present, is hydrogen, lower alkyl, or lower alkenyl, where R ₆ is absent when R ₂ is ═O;
[146] Y ₁ is a covalent bond, alkylene or alkenylene;
[147] Y ₂ is alkylene;
[148] Y ₃ is alkylene; And
[149] Z is selected from the group consisting of covalent bonds, O, S, NH, N-lower alk, alkylene, alkenylene and alkynylene, provided that Z is O, S, NH or N-lower alkyl, ₁ is not a covalent bond; Provided that Y ₁ and Z may be combined to be a covalent bond;
[150] Provided that R ₁ is not 6-CN-2-pyridyl;
[151] Provided that when R ₅ is 3,4-dimethoxy-phenyl, R ₁ is CH ₃ (CH ₂ ) ₅ O-phenyl; 2-cyclopentyl-phenyl; 2-Cl-phenyl; 2-CN-phenyl; 2- (3-furanyl) phenyl; Or 4- (1,2-benzisothiazole);
[152] And when R ₅ is 4-methoxy-phenyl, R ₁ is 2-cyclopentyl-phenyl; 2-CH ₃ -phenyl; 2-benzyl-phenyl; 3-CH ₃ , 4-CH ₃ SO ₂ -phenyl; Not 4- (1,2-benzisothiazole);
[153] And provided that when R ₅ is 4-Cl-phenyl, R ₁ is 2-CH ₃ -phenyl; 5-iso-propyl-phenyl; 2-CH ₃ -phenyl; 4-CH ₃ -phenyl; Phenyl; 2-Cl-phenyl; 4-Cl-phenyl; 2-methoxy; 4-CH ₃ CHCH-phenyl; 3,4CH ₃ -phenyl; 2,3CH ₃ -phenol; 2,3CH ₃ -phenyl; 2-iso-propyl; 5-CH ₃ -phenyl; Pyridyl; 1-imidazole; Or 4- (1,2-benzisothiazole); And
[154] And provided that when R ₅ is 3,5-dimethyl or 4-methoxy-phenyl, R ₁ is not 4-CH ₃ , 6-CN-2-pyridyl or thiophene carboxamide]. Optionally acceptable salts and complexes thereof; Wherein the compound has an IC ₅₀ ≦ ₁₀ μM in a calcium receptor inhibitor assay]
[155] Maxine Gowen et al. Also called a compound called NPS-2143 with CaSR antagonism.
[156]
[157] Was orally administered to OVX rats, and the effects on the bone formation of NPS-2143 were tested by measuring their blood concentration and bone density, and the results are reported [J. Clin. Invest., 105, 1595-1604 (2000).
[158] According to this, NPS-2143 significantly promoted the release of PTH, but had no direct effect on osteoblasts and osteoclasts in vitro, and as a result, there was no bone increase without bone loss. As one of the causes, it is pointed out that the blood half-life of NPS-2143 is too long. In other words, when the rat PTH (1-34) was administered at a dose of 5 µg / kg to the OVX rat, the blood PTH concentration peaked at about 175 pg / ml after 30 minutes, and returned to its original state after 2 hours. . When NPS-2143 was administered at a dose of 100 μmol / kg, the PTH concentration continued to increase even after the blood PTH concentration reached about 115 pg / ml after 30 minutes, and the concentration was about 140 pg / ml even after 4 hours [ J. Clin. Invest., 105, 1595-1604 (2000), page 1598, see FIG. 3].
[159] At this time, the blood concentration of NPS-2143 itself remained elevated to 100ng / ml or more even after 8 hours of administration, and it was 24 hours later that it could not be detected because it became 10ng / ml or less.
[160] The Maxine-Gowen et al. Document shows that calcium receptor antagonists with too long blood half-lives have the same result as if PTH was continuously administered, and bone growth could never be expected.
[161] An object of the present invention is to provide a compound having calcium receptor antagonism. The present invention also relates to diseases involving abnormalities of calcium homeostasis, ie osteoporosis, epithelial hypoplasia, osteomyeloma, periodontal disease, osteoporosis, osteoarthritis, chronic arthritis, pazette disease, liquid hypercalcemia, It is an object of the present invention to provide a pharmaceutical composition capable of oral administration and intermittent administration, which is effective as a therapeutic drug for autosomal dominant hypocalcemia, in particular, for treating osteoporosis. It is another object of the present invention to provide a synthetic intermediate of a compound having calcium receptor antagonism.
[1] The present invention relates to compounds having a calcium sensing receptor (CaSR, hereinafter referred to simply as calcium receptor) antagonism, pharmaceutical compositions containing these compounds, in particular calcium receptor antagonists and therapeutic agents for osteoporosis, and intermediate compounds useful for synthesizing these compounds. will be.
[234] 1 is a diagram showing changes over time of serum PTH concentrations when 30 mg / kg of the compound of Example 22 was administered to a rat.
[235] Fig. 2 is a graph showing changes over time of serum PTH concentrations when 30 mg / kg of the compound of Example 23 was administered to rats.
[236] Fig. 3 is a graph showing changes over time of serum PTH concentrations when 30 mg / kg of the compound of Example 24 was administered to rats.
[237] Fig. 4 is a graph showing the change over time of serum PTH concentration when 100 mg / kg of the compound of Comparative Example 1 was administered to rats.
[238] Fig. 5 is a diagram showing changes over time of serum PTH concentrations when 30 mg / kg of NPS-2143 was administered to rats.
[239] Embodiment of the invention
[240] Definitions of terms used in the present specification are as follows.
[241] An "aryl group" is an aromatic hydrocarbon group having 6 to 12 carbon atoms, and may be partially saturated. For example, a phenyl group, a biphenyl group, an indenyl group, a naphthyl group, etc. are mentioned, Preferably it is a phenyl group or a naphthyl group, Especially preferably, it is a phenyl group. These aryl groups may be substituted with the substituent mentioned later. The position of the number of bonds of these aryl groups and the position of the substituent in the case of having a substituent are not particularly limited as long as they are chemically acceptable.
[242] "Heteroaryl group" refers to a 5 to 6 membered unsaturated ring containing 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom or a sulfur atom in the ring, and also includes a condensed ring with a benzene ring or other heterocycle. . As examples of these heteroaryl groups, for example, pyrrolyl group, furyl group, thienyl group, imidazolyl group, oxazolyl group, thiazolyl group, pyrazolyl group, isoxazolyl group, isothiazolyl group, oxdiazolyl group , Triazolyl group, indolyl group, benzofuryl group, benzothienyl group, benzimidazolyl group, benzoxazolyl group, benzothiazolyl group, pyridyl group, pyrimidinyl group, quinolyl group or isoquinolyl group Can be. Preferably, they are a benzofuryl group, benzothienyl group, benzimidazolyl group, benzoxazolyl group, benzthiazolyl group, pyridyl group or quinolyl group. These heteroaryl groups may be substituted with the substituent mentioned later. The position of the number of bonds of these heteroaryl groups and the position of the substituent in the case of having a substituent are not particularly limited as long as they are chemically acceptable.
[243] The "halogen atom" is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a fluorine atom or a chlorine atom, and particularly preferably a chlorine atom.
[244] "C _1-6 alkyl group" refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert -Butyl group, pentyl group, isopentyl group, tert-pentyl group or hexyl group, and the like, and preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl groups C _1-4 alkyl group selected.
[245] A "halo (C _1-6 ) alkyl group" refers to a haloalkyl group in which the "C _1-6 alkyl group" is substituted with one or more halogen atoms, and the substitution position is not particularly limited as long as it is chemically acceptable. Examples of the "halo (C _1-6 ) alkyl group" include fluoromethyl group, difluoromethyl group, trifluoromethyl group, chloromethyl group, dichloromethyl group, trichloromethyl group, bromomethyl group, dibromomethyl group and tribromo. Methyl group, iodomethyl group, diiodomethyl group, triiodomethyl group, 2-fluoroethyl group, 2,2-difluoroethyl group, 2,2,2-trifluoroethyl group, 2-chloroethyl group, 2,2 -Dichloroethyl group, 2,2,2-trichloroethyl group, 2-bromoethyl group, 2,2-dibromoethyl group, 2,2,2-tribromoethyl group, 3-chloropropyl group or 4-chlorobutyl A group etc. are mentioned, Preferably it is a haloC _1-2 alkyl group of a trifluoromethyl group or a 2,2,2- trichloroethyl group.
[246] The "hydroxy (C _1-6 ) alkyl group" represents a hydroxyalkyl group in which the "C _1-6 alkyl group" is substituted with a hydroxyl group, and the substitution position is not particularly limited as long as it is chemically acceptable. Examples of the "hydroxy (C _1-6 ) alkyl group" include hydroxymethyl group, 1-hydroxyethyl group, 2-hydroxyethyl group, 1-hydroxypropyl group, 2-hydroxypropyl group, and 3-hydroxypropyl group. Group, 2-hydroxy-1-methylethyl group, 1-hydroxybutyl group, 2-hydroxybutyl group, 3-hydroxybutyl group, 4-hydroxybutyl group, 3-hydroxy-2-methylpropyl group , 2-hydroxy-1,1-dimethylethyl group, 5-hydroxypentyl group or 6-hydroxyhexyl group, and the like, and preferably, a hydroxymethyl group, 2-hydroxyethyl group and 3-hydroxypropyl group. Hydroxy (C _1-4 ) alkyl group selected from the group and 4-hydroxybutyl group.
[247] "C _1-6 alkoxy group" refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, tert-butoxy group, pentyloxy group, tert-pentyloxy group or hexyloxy group, etc. are mentioned, Preferably it is a methoxy group, an ethoxy group, propoxy group, isopropoxy group, butoxy group or tert-butoxy group. C _1-4 alkoxy group selected.
[248] If the "C _1-6 alkoxy (C _1-6) alkyl group" represents an alkoxy group substituted with the above "C _1-6 alkyl group" in the "C _1-6 alkoxy group", the position of substitution is chemically acceptable, It is not specifically limited. Examples of the "C _1-6 alkoxy (C _1-6 ) alkyl group" include methoxymethyl group, ethoxymethyl group, propoxymethyl group, butoxymethyl group, pentyloxymethyl group, hexyloxymethyl group, 1-methoxyethyl group and 1- Ethoxyethyl group, 2-methoxyethyl group, 2-ethoxyethyl group, 1-methoxypropyl group, 1-ethoxypropyl group, 2-methoxypropyl group, 2-ethoxypropyl group, 3-methoxypropyl group , 3-ethoxypropyl group, 2-methoxy-1-methylethyl group, 1-methoxybutyl group, 1-ethoxybutyl group, 2-methoxybutyl group, 2-ethoxybutyl group, 3-methoxy Butyl group, 3-ethoxybutyl group, 4-methoxybutyl group, 4-ethoxybutyl group, 3-methoxy-2-methylpropyl group, 2-methoxy-1,1-dimethylethyl group, 2-e A methoxy-1,1-dimethylethyl group, 5-methylpentyl group, 6-methoxyhexyl group, etc. are mentioned, Preferably a methoxymethyl group, an ethoxymethyl group, a propoxymethyl group, butoxymethyl group, 2-methoxy C _1-4 selected from ethyl group, 3-methoxypropyl group and 4-methoxybutyl group Alkoxy (C _1-4 ) alkyl group.
[249] "Halo (C _1-6 ) alkoxy group" refers to a haloalkoxy group in which the "C _1-6 alkoxy group" is substituted with one or more halogen atoms, and the substitution position is not particularly limited as long as it is chemically acceptable. Examples of the "halo (C _1-6 ) alkoxy group" include fluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, chloromethoxy group, dichloromethoxy group, trichloromethoxy group, bromomethoxy group, Dibromomethoxy group, tribromomethoxy group, iodomethoxy group, diiodomethoxy group, triiodomethoxy group, 2-fluoroethoxy group, 2,2-difluoroethoxy group, 2, 2,2-trifluoroethoxy group, 2-chloroethoxy group, 2,2-dichloroethoxy group, 2,2,2-trichloroethoxy group, 2-bromoethoxy group, 2,2- Dibromoethoxy group, 2,2,2-tribromoethoxy group, 3-chloropropoxy group or 4-chlorobutoxy group, and the like, and preferably trifluoromethoxy group or 2,2,2 It is a halo (C _1-2 ) alkoxy group of a -trichloroethoxy group.
[250] "C _1-6 alkylthio group" refers to a straight or branched chain alkylthio group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, for example, methylthio group, ethylthio group, propylthio group, isopropylthio group , Butylthio group, tert-butylthio group, pentylthio group, tert-pentylthio group, or hexylthio group, and the like, and preferably, methylthio group, ethylthio group, propylthio group, isopropylthio group, C _1-4 alkylthio group selected from butylthio group or tert-butylthio group.
[251] "C _1-6 alkylsulfanyl group" refers to a straight or branched chain alkylsulfanyl group having 1 to 6 carbon atoms, for example, methylsulfanyl group, ethylsulfanyl group, propylsulfanyl group, isopropylsulfanyl group, butylsulfanyl group, tert- Butylsulfanyl group, pentylsulfanyl group, tert-pentylsulfanyl group or hexylsulfanyl group, and the like, and preferably 1 to 4 methylsulfanyl group, ethylsulfanyl group, propylsulfanyl group, isopropylsulfanyl group, butylsulfanyl group or tert- Butyl sulfanyl group.
[252] "C _1-6 alkylsulfonyl group" refers to a straight or branched chain alkylsulfonyl group having 1 to 6 carbon atoms, for example, methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropylsulfonyl group, butylsulfonyl group, tert- Butylsulfonyl group, pentylsulfonyl group, tert-pentylsulfonyl group or hexylsulfonyl group, and the like, and preferably 1 to 4 methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropylsulfonyl group, butylsulfonyl group or tert- Butyl sulfonyl group.
[253] "C _1-6 alkyl sulfamoyl group" refers to a sulfamoyl group substituted with "C _1-6 alkyl group" above, for example, methyl sulfamoyl group, ethyl sulfamoyl group, propyl sulfamoyl group, isopropyl sulfamo Diary, butyl sulfamoyl group, tert-butyl sulfamoyl group, pentyl sulfamoyl group, tert-pentyl sulfamoyl group or hexyl sulfamoyl group, etc., Preferably they are C1-C4 methyl sulfamoyl group, ethyl sulfamoyl group, Propyl sulfamoyl group, isopropyl sulfamoyl group, butyl sulfamoyl group or tert-butyl sulfamoyl group.
[254] A "di (C _1-6 ) alkylsulfamoyl group" refers to a sulfamoyl group substituted with 2 "C _1-6 alkyl groups", for example, a dimethyl sulfamoyl group, a diethyl sulfamoyl group, a dipropyl sulfamoyl group , Diisopropyl sulfamoyl group, dibutyl sulfamoyl group, diisobutyl sulfamoyl group, di-tert-butyl sulfamoyl group, dipentyl sulfamoyl group, ethyl methyl sulfamoyl group, methylpropyl sulfamoyl group, butyl methyl sulfonate Pamoyl group, ethyl propyl sulfamoyl group or ethyl butyl sulfamoyl group. Preferably, they are a dimethyl sulfamoyl group, a diethyl sulfamoyl group, or a dipropyl sulfamoyl group.
[255] "(C _1-6 alkoxy) carbonyl group" refers to an alkoxycarbonyl group where the C _1-6 alkoxy moiety is exemplified as the "C _1-6 alkoxy group", for example, methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, iso Propoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, tert-butoxycarbonyl group, pentyloxycarbonyl group or hexyloxycarbonyl group. Preferably they are (C _1-4 alkoxy) carbonyl groups selected from methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group or tert-butoxycarbonyl group.
[256] "C _1-7 acyl group" represents an alkanoyl group or an aroyl group having 1 to 7 carbon atoms, and may include formyl group, acetyl group, propionyl group, butyryl group, pivaloyl group, or benzoyl group. Preferably it is a formyl group, an acetyl group, pivaloyl group, or a benzoyl group.
[257] "(C _1-6 alkyl) carbamoyl group" refers to an alkylcarbamoyl group in which a carbamoyl group is substituted with a C _1-6 alkyl group exemplified as the "C _1-6 alkyl group", for example, a methylcarbamoyl group, Ethyl carbamoyl group, propyl carbamoyl group, isopropyl carbamoyl group, butyl carbamoyl group, tert- butyl carbamoyl group, pentyl carbamoyl group, tert-pentyl carbamoyl group, or hexyl carbamoyl group, etc. are mentioned, Preferably, it is a (C _1-4 alkyl) carbamoyl group selected from methylcarbamoyl group, ethylcarbamoyl group, propylcarbamoyl group, isopropylcarbamoyl group, butylcarbamoyl group or tert-butylcarbamoyl group.
[258] A "di (C _1-6 alkyl) carbamoyl group" refers to a dialkylcarbamoyl group in which a carbamoyl group is substituted with the "C _1-6 alkyl group" two times, and the type of the alkyl group may be different. For example, dimethylcarbamoyl group, diethylcarbamoyl group, dipropylcarbamoyl group, diisopropylcarbamoyl group, dibutylcarbamoyl group, di-tert-butylcarbamoyl group, dipentylcarbamoyl group, di-tert -Pentyl carbamoyl group, dihexyl carbamoyl group, methyl ethyl carbamoyl group, methyl propyl carbamoyl group, methyl butyl carbamoyl group, ethyl propyl carbamoyl group, ethyl butyl carbamoyl group, etc. are mentioned, Preferably, (C _1-4 alkyl) carbamoyl group selected from dimethylcarbamoyl group, diethylcarbamoyl group, dipropylcarbamoyl group, dibutylcarbamoyl group or di-tert-butylcarbamoyl group.
[259] "C _1-6 alkylamino group" refers to an alkylamino group in which an amino group is substituted with the "C _1-6 alkyl group", for example, methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, tert -Butylamino group, pentylamino group, isopentylamino group, tert-pentylamino group or hexylamino group, and the like, and preferably methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group and tert-butyl C _1-4 alkylamino group selected from amino groups.
[260] The "di (C _1-6 ) alkylamino group" refers to a dialkylamino group in which the amino group is substituted with the "C _1-6 alkyl group" two times, and the type of the alkyl group may be different. For example, dimethylamino group, ethylmethylamino group, diethylamino group, methylpropylamino group, ethylpropylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di-tert-butylamino group, dipentylamino group, Diisopentylamino group, di-tert-pentylamino group or dihexylamino group, and the like, and preferably, dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group or di C _1-4 alkylamino group selected from -tert-butylamino group.
[261] "C _1-7 acylamino group" denotes an amino group substituted by the above "C _1-7 acyl group", for example, formyl group, acetyl group, propionyl group, butyryl group, or alkanoyl such as pivaloyl group Amino group; And an aroylamino group such as a benzoylamino group which may have 1 to 3 substituents in an aryl group. Preferred are formylamino group, acetylamino group, pivaloylamino group and benzoylamino group.
[262] "C _3-7 cycloalkyl group" represents a C3-7, preferably 3-6 cyclic alkyl group, and examples thereof include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group and the like. And C _3-5 cycloalkyl groups such as a cyclopropyl group, a cyclobutyl group, and a cyclopentyl group, more preferably a cyclopropyl group or a cyclobutyl group, and particularly preferably a cyclopropyl group.
[263] "C _2-6 alkenyl group" refers to an alkenyl group having 2 to 6 carbon atoms, for example, a vinyl group, 1-propenyl group, allyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pente And a phenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group or a 5-hexenyl group, and the like, and preferably a C _2-4 alkenyl group such as a vinyl group or an allyl group.
[264] "C _2-6 alkynyl group" represents an alkynyl group having 2 to 6 carbon atoms, preferably 2 to 4 carbon atoms, for example, an ethynyl group, 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-buty And a nilyl group, 3-butynyl group, 1-pentynyl group, 2-pentynyl group, 3-pentynyl group, 4-pentynyl group, or 5-hexynyl group, and the like, and preferably, an ethynyl group, 1-propynyl group, or 2- C _2-4 alkynyl group selected from propynyl group.
[265] "Aralkyl group" represents an arylalkyl group in which the "C _1-6 alkyl group" is substituted with the "aryl group", and the substitution position is not particularly limited as long as it is chemically acceptable. Examples of the "aralkyl group" include benzyl group, phenethyl group, 3-phenylpropyl group, 4-phenylbutyl group, 5-phenylpentyl group, 6-phenylhexyl group, 1-naphthylmethyl group, 2-naphthylmethyl group and the like. Can be mentioned. Preferably a phenyl (C _1-2 ) alkyl group of a benzyl or phenethyl group in which the "aryl" moiety is phenyl and the "alkyl" moiety is methyl or ethyl.
[266] "C _1-6 alkylsulfonyloxy group" refers to an alkylsulfonyloxy group in which the C _1-6 alkyl moiety is the "C _1-6 alkyl group", for example, a methylsulfonyloxy group, an ethylsulfonyloxy group, and a propylsulfonyloxy group. , Isopropylsulfonyloxy group, butylsulfonyloxy group, isobutylsulfonyloxy group, tert-butylsulfonyloxy group, pentylsulfonyloxy group, isopentylsulfonyloxy group, tert-pentylsulfonyloxy group and hexylsulfonyloxy group C _1-4 selected from methylsulfonyloxy group, ethylsulfonyloxy group, propylsulfonyloxy group, isopropylsulfonyloxy group, butylsulfonyloxy group, isobutylsulfonyloxy group or tert-butylsulfonyloxy group. Alkylsulfonyloxy group.
[267] "C _1-3 alkylenedioxy" represents a methylenedioxy group, an ethylenedioxy group or a propylenedioxy group, preferably a methylenedioxy group or an ethylenedioxy group, and particularly preferably a methylenedioxy group.
[268] "C _1-6 alkylene group" represents an alkylene group having 1 to 6 carbon atoms, and examples thereof include a methylene group, an ethylene group, a propylene group, a butylene group, a pentylene group or a hexylene group. It is preferably a C _1-4 alkylene group selected from methylene group, ethylene group and propylene group.
[269] "C _2-6 alkynylene group" refers to an alkynylene group having 2 to 6 carbon atoms, preferably 2 to 3 carbon atoms, for example, a vinylene group, a 1-propenylene group, a 2-propenylene group, a 1-butenylene group , 2-butenylene group, 3-butenylene group, 1-pentenylene group, 2-pentenylene group, 3-pentenylene group, 4-pentenylene group, 1-hexenylene group, 2-hexenylene group, 3 -Hexenylene group, 4-hexenylene group, 5-hexenylene group, etc. are mentioned. Preferably it is a C _2-3 alkynylene group chosen from a vinylene group, a 1-propenylene group, and 2-propenylene group.
[270] The aryl group and heteroaryl group of the present invention is a halogen atom, a C _1-6 alkyl group, a halo (C _1-6 ) alkyl group, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, hydroxyl group, C _1-6 alkoxy groups, halo (C _1- 6) alkoxy group, a mercapto group, C _1-6 alkylthio, C _1-6 alkyl sulfanyl group, a C _1-6 alkylsulfonyl group, aminosulfonyl group , C _1-6 alkylsulfamoyl group, di (C _1-6 ) alkylsulfamoyl group, carboxyl group, (C _1-6 alkoxy) carbonyl group, C _1-7 acyl group, carbamoyl group, (C _1-6 alkyl ) Carbamoyl group, di (C _1-6 alkyl) carbamoyl group, cyano group, nitro group, amino group, C _1-6 alkylamino group, di (C _1-6 ) alkylamino group, C _1-7 acylamino group, C _1-3 alkylenedioxy group,
[271]
[272] It may be substituted with 1 to 3 substituents selected from (wherein R ^A represents a (C _1-6 alkoxy) carbonyl group or a carboxy group, and R ^B represents a hydrogen atom or a C _1-6 alkyl group).
[273] As a "salt" of the compound of the present invention, inorganic acid addition salts such as hydrochloride, hydrobromide, sulfate, phosphate or nitrate; Acetate, propionate, succinate, glucolate, lactate, malate, oxalate, tartarate, citrate, maleate, fumarate, methanesulfonate, benzenesulfonate, p-toluenesulfonate or ascorbin Organic acid addition salts such as acid salts; Although amino acid addition salts, such as an asparagine salt or glutamate, are contained, it is not limited to these. Preferred salts are hydrochloride or fumarate, in particular fumarate.
[274] The present invention contains a solvate, wherein the "solvate" of the compound is a solid or solution such as crystal or amorphous, and the compound of the present invention is a solvent molecule such as water, alcohol, van der Waals force or electrostatic Interactions, hydrogen bonds, charge transfer bonds, coordination bonds, etc. means a relatively weak bond. In some cases, the solvent may be absorbed in a solid state such as hydrate or alcohol-containing water. Preferred solvates are hydrates.
[275] A "prodrug" of a compound is a derivative of the compound of the present invention which has a group that can be chemically or metabolically decomposed and which is medicinally active by hydrolysis or solvolysis or under physiological conditions.
[276] Various isomers, such as an optical isomer, a stereoisomer, a geometric isomer, tautomer, etc., can exist in the compound represented by general formula [I], [I-2], and [I-3] which concern on this invention. The scope of the invention includes all these isomers and mixtures thereof.
[277] In the compound represented by the general formula [I] according to the present invention, R ¹ is preferably an aryl group, more preferably a phenyl group or a naphthyl group, and particularly preferably a phenyl group. R ¹ is preferably a halogen atom, C _1-4 alkyl, hydroxy (C _1-6) alkyl group as a substituent when the aryl date, C _1-6 alkoxy (C _1-6) alkyl group, a hydroxyl group, C _1-4 Alkoxy group, cyano group, nitro group or C _1-3 alkylenedioxy group, more preferably chlorine atom, methyl group, hydroxymethyl group, methoxy group, cyano group, nitro group, hydroxyl group or methylenedioxy, particularly preferred Preferably it is a methyl group, a hydroxymethyl group, a methoxy group, or a methylenedioxy group.
[278] When R ¹ is a heteroaryl group, it is preferably selected from thienyl group, furyl group, pyridyl group and thiazolyl group, and as a substituent when R ¹ is a heteroaryl group, preferably a C _1-6 alkyl group or a halogen atom, Especially preferably, they are a methyl group or a bromine atom.
[279] R ² is preferably a C _1-4 alkyl group, C _3-5 cycloalkyl group, C _2-4 alkenyl group or aralkyl group which may be optionally substituted and may be branched, and the substituent of C _1-4 alkyl group is C _{1 -4} alkoxy groups are preferred. As R <^2> , More preferably, they are a methyl group, an ethyl group, a cyclopropyl group, or a cyclobutyl group, Most preferably, they are a methyl group or a cyclopropyl group, Especially preferably, they are a cyclopropyl group.
[280] R ³ is preferably a hydroxyl group, and R ⁴ is preferably a hydrogen atom. R ⁵ and R ⁶ are each preferably a methyl group. R ⁷ is preferably an aryl group, more preferably a phenyl group or a naphthyl group. The substituent of R ⁷ is preferably a C _1-6 alkyl group, a C _1-6 alkoxy group, a hydroxyl group or a C _1-3 alkylenedioxy group, more preferably a C _1-4 alkyl group, a C _1-4 alkoxy group or It is a C _1-3 alkylenedioxy group, Most preferably, it is a C _1-4 alkyl group or a C _1-4 alkoxy group, Especially preferably, it is a methyl group or a methoxy group. R ⁷ is preferably a naphthyl group, 4-methoxy-3-methylphenyl group or 3,4-methyldioxyphenyl group, and particularly preferably naphthyl group or 4-methoxy-3-methylphenyl group. X ¹ is preferably a C _1-6 alkylene group, and particularly preferably methylene group. X ² is preferably a methylene group. X ³ is preferably a methylene group. X ⁴ and X ⁵ are each preferably a single bond.
[281] R ¹¹ is preferably a hydrogen atom, a halogen atom, a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, a hydroxyl group, a C _1-4 alkoxy group, It is a cyano group or a nitro group, More preferably, it is a hydrogen atom, a chlorine atom, a methyl group, a hydroxymethyl group, a methoxy group, a cyano group, a hydroxyl group, or a nitro group, Especially preferably, it is a hydrogen atom.
[282] R ¹² is preferably a hydrogen atom, a halogen atom, a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, a hydroxyl group, a C _1-4 alkoxy group, It is a cyano group or a nitro group, More preferably, it is a chlorine atom, a methyl group, a hydroxymethyl group, a methoxy group, a cyano group, a hydroxyl group, or a nitro group, Especially preferably, they are a methyl group, a hydroxymethyl group, or a methoxy group.
[283] R ²¹ is preferably a methyl group, an ethyl group, a cyclopropyl group or a cyclobutyl group, more preferably a methyl group or a cyclopropyl group, and particularly preferably a cyclopropyl group.
[284]
[285] Solid coordination of
[286]
[287] This is preferred.
[288] Preferable aspect of compound [I] of this invention is compound [I-2], and compound [I-3] is more preferable.
[289] Specific examples of preferred compounds of the present invention are given below:
[290] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methoxyphenyl) methoxy] propan-2-ol,
[291] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methylphenyl) methoxy] propan-2-ol,
[292] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (phenyl) methoxy] propan-2-ol,
[293] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) ethoxy] propan-2-ol,
[294] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methylphenyl) ethoxy] propan-2-ol,
[295] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) propoxy] propan-2-ol,
[296] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-cyanophenyl) ethoxy] propan-2-ol,
[297] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (3-methoxyphenyl) ethoxy] propan-2-ol,
[298] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (3-methylphenyl) ethoxy] propan-2-ol and
[299] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-hydroxymethylphenyl) methoxy] propan-2-ol.
[300] In the case of using the compound of the present invention as a medicine, the compound itself (the free body), the salt of the compound, the solvate of the compound or the prodrug of the compound, but the preferred form is the free body, the salt of the compound or the solvate of the compound And particularly preferably a salt of the compound.
[301] Next, the manufacturing method of the compound represented by general formula [I] which concerns on this invention is demonstrated concretely. However, of course, this invention is not limited to these manufacturing methods. What is necessary is just to implement a construction procedure from the site | part which is easy to implement suitably when constructing the compound of this invention. Moreover, when there is a reactive functional group in each process, what is necessary is just to perform protection and deprotection suitably, and reagents other than the illustrated reagent can be used suitably in order to accelerate progress of reaction.
[302] All the compounds obtained in each step can be isolated and purified by a conventional method, but in some cases, can proceed to the next step without isolation and purification.
[303]
[304] (X represents a halogen atom, L ¹ and L ² are each a leaving group such as a halogen atom and a sulfonyloxy group (eg, 3-nitrobenzenesulfonyloxy group, p-toluenesulfonyloxy group, benzenesulfonyloxy group, p) -Bromobenzenesulfonyloxy group, methanesulfonyloxy group or trifluoromethanesulfonyloxy group, etc.), R3 ^' represents an oxygen atom or a sulfur atom, and each other symbol is the same as the above.)
[305] 1st process
[306] Compound (6) is obtained by reacting an aldehyde compound (4) and a Grignard reagent (5) at -80 ° C to room temperature in diethyl ether, tetrahydrofuran, 1,4-dioxane or the like or a mixed solvent thereof. Lose. What is necessary is just to implement a well-known method of preparing a Grignard reagent.
[307] Alternatively, the ketone compound (4 ') is diethyl ether, tetrahydrofuran, 1,4-dioxane, isopropanol, or the like, or a mixed solvent thereof, at -10 ° C to room temperature, lithium aluminum hydride, sodium borohydride, or lithium borohydride Compound (6) is also obtained by performing a reduction reaction with a reducing agent such as the above. In this case, a subtitle reduction using a subtitle reduction agent such as B-chlorodiisopinecamphor borane or dichloro [(S)-(-) 2,2'-bis (diphenylphosphino) -1,1'- A subhydrogenation reaction using ruthenium complexes such as vinaphthyl] ruthenium (II) may be carried out.
[308] 2nd process
[309] Compound (6) obtained in the first step is N, N-dimethylformamide, dimethyl sulfoxide, tetrahydrofuran or the like, or a mixed solvent thereof, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate Reacting the compound (7) at 0 ° C to room temperature in the presence of a base such as potassium hydrogencarbonate, triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, pyridine, 4-dimethylaminopyridine, or the like Compound (8) is obtained. In this case L ¹ is a leaving group which is more reactive than L ² .
[310] Moreover, when R <^3> is a hydroxyl group or a mercapto group, R <^4> is a hydrogen atom and X <^2> is a methylene group, the compound (7 ') may be used instead of compound (7). In this case, alkylammonium sulfate, such as tetrabutylammonium sulfate, can be added.
[311] Stereoselective reaction can be performed by selection of a reagent and a leaving group to be used.
[312] 3rd process
[313] Compound (8) obtained in the second step is a base material such as N, N-dimethylformamide, dimethyl sulfoxide, tetrahydrofuran or the like, or a mixed solvent thereof, such as sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate. Then, the compound represented by general formula [I] is obtained by making compound (9) react at 0 degreeC-room temperature.
[314] Compound (8 ') and compound (9) may be reacted at room temperature to reflux in methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, toluene, or a mixed solvent thereof. By reacting, the compound in which R <^3> is a hydroxyl group or a mercapto group, R <^4> is a hydrogen atom and X <^2> is a methylene group in the compound represented by general formula [I] is obtained. In this case, it is preferable to add alkali perchlorate, such as lithium perchlorate.
[315] When acid addition salt of the compound represented by general formula [I] is desired, a well-known method can be used. For example, the compound represented by the formula [I] may be water, methanol, ethanol, n-propanol, isopropanol, diethyl ether, tetrahydrofuran, 1,4-dioxane, ethyl acetate, dichloromethane, 1,2-dichloroethane or What is necessary is just to filter-crystallize or concentrate under reduced pressure, melt | dissolving in chloroform etc. or these mixed solvents, adding the said solvent which melt | dissolved the desired acid, and depositing.
[316] When the acid addition salt of the compound represented by the formula [I] is converted into the vitreous, the acid addition salt of the formula [I] is converted into sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, or the like. The vitreous of the compound represented by the formula [I] can be obtained by partitioning the aqueous solution of the base with a solvent such as ethyl acetate, dichloromethane, 1,2-dichloroethane, chloroform, methylethylketone or toluene. .
[317] The preparation method of a compound (4 ') can be implemented with the following method.
[318]
[319] (Each symbol is the same as above)
[320] 4th process
[321] Compound (10) in the presence of a base such as triethylamine, N, N-diisopropylethylamine in a solvent such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran and 1,4-dioxane Compound (11) is obtained by reacting N, O-dimethylhydroxylamine or its salt.
[322] 5th process
[323] The compound (11) and the Grignard reagent (5) obtained in the fourth step are reacted at -80 ° C to room temperature in diethyl ether, tetrahydrofuran, 1,4-dioxane or the like or a mixed solvent thereof to obtain a compound ( 4 ') is obtained.
[324] The manufacturing method of compound (9) can be implemented with the following method.
[325]
[326] (Rh represents carboxylic acid protecting groups, such as a benzyl group and tert- butyl group, and each other symbol is the same as the above)
[327] 6th process
[328] Compound (14) is obtained by reacting compound (12) with compound (13) in a solvent such as tetrahydrofuran and n-hexane in the presence of a base such as n-butyllithium and hexamethylphosphoramide.
[329] 7th process
[330] This step is a step of obtaining the compound (15) by the luteus potential from the compound (14) obtained in the sixth step. Compound (14) is reacted with an alkyl halide carbonate, such as ethyl chlorocarbonate, in the presence of a base such as triethylamine, N, N-diisopropylethylamine, or the like in water, acetone, methyl ethyl ketone, or a mixed solvent thereof. Subsequently, the compound obtained by making sodium azide react is made to react under heating, and then compound (15) is obtained by making it react with the alcohol represented by Rh-OH.
[331] 8th process
[332] This step is a step of deprotecting the -CO ₂ Rh of compound (15) obtained in the seventh step, is carried out when the method is normally carried out to deprotecting the protecting group. For example, when Rh is a benzyl group, in a solvent such as methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, 1,4-dioxane, a catalyst such as palladium carbon, palladium black, palladium hydroxide, or rani-nickel is used. Compound (9) is obtained by subjecting compound (15) to a hydrogenation reaction. For example, when Rh is a tert-butyl group, hydrogen chloride, sulfuric acid, bromination in water, methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, 1,4-dioxane, acetic acid or the like or a mixed solvent thereof Compound (9) is obtained by making it react using acids, such as hydrogen.
[333] Moreover, when compound (9 ') whose -X <^3> -X <^4> -X <^5> -is methylene is desired in compound (9), you may carry out by the following method.
[334]
[335] (Each symbol is the same as above)
[336] 9th process
[337] Compound (18) is obtained by reacting compound (17) with compound (16) in a solvent such as tetrahydrofuran and n-hexane in the presence of a base such as n-butyllithium.
[338] 10th process
[339] When compound (18) obtained at the ninth step is reacted with sulfuric acid in acetonitrile and acetic acid, compound (19) is obtained.
[340] 11th process
[341] Compound (19) obtained in the tenth step is water, methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, 1,4-dioxane, acetic acid or the like or a mixed solvent thereof, such as hydrogen chloride, sulfuric acid, hydrogen bromide By reacting under heating using an acid, the compound (9 ') is obtained.
[342] Furthermore, compound (19) is used in a solvent such as water, methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, 1,4-dioxane and ethylene glycol, using a base such as sodium hydroxide, potassium hydroxide or lithium hydroxide. Compound (9 ') is obtained also by making it react on heating.
[343] Compound (9 ') can also be produced by the following method.
[344]
[345] (Each symbol is the same as above)
[346] 12th process
[347] Trialkylhalogenated silane, such as tetraalkylammonium halides, such as tetrabutylammonium fluoride, and tert-butyldimethylchlorosilane, in compound (21) in solvents, such as tetrahydrofuran, N, N- dimethylformamide, and dimethyl sulfoxide When compound is reacted with compound (20) below, compound (22) is obtained.
[348] 13th process
[349] When the compound (22) obtained in the twelfth step is halogenated using a halogenating agent such as thionyl chloride or oxalyl chloride, the compound (23) is obtained. In this reaction, the halogenating agent itself may be used as a solvent, or solvents such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, and 1,4-dioxane may be used.
[350] 14th process
[351] Compound (23) obtained in the thirteenth step is a catalyst such as palladium carbon, palladium black, palladium hydroxide in solvents such as methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, 1,4-dioxane and ethyl acetate Compound (24) is obtained by hydrogenation in the presence of hydrogen. In this reaction, it is preferable to apply a slight pressure.
[352] 15th process
[353] Compound (24) obtained in the fourteenth step is subjected to a hydrogenation reaction using a catalyst such as Raney-Nickel in a solvent such as methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, or 1,4-dioxane. Compound (9 ') is obtained. In this reaction, it is preferable to apply a slight pressure.
[354] The intermediate compound shown in the said manufacturing method is useful as an intermediate of compound [I]. Among these intermediate compounds, the following compounds are novel compounds.
[355] (A) Compound [II] consisting of a part of Compound (6) and a compound obtained in Step 2 of Example 57 to be described later, a salt thereof, and a solvate thereof (R ^{11 '} is a C _1-4 alkyl group, hydroxy (C _{1 An} alkyl group or a C _1-4 alkoxy group is preferred),
[356] (B) Compound [III], a salt thereof and a solvate thereof (R ^{11 "} is preferably a C _1-4 alkoxy group) composed of a compound obtained in Step 2 of Example 58 to be described later with a part of Compound (4 '),
[357] (C) Compound (14), Compound (15) and Compound (24) (wherein R ⁵ and R ⁶ in Formulas (14), (15) and (24) are methyl groups, and also -X ³ -X ⁴ -X ⁵ -R ⁷ group is 2-naphthylmethyl group), the compound [IV], its salt, and its solvate.
[358] The compound represented by general formula [I] concerning this invention obtained in this way has the outstanding calcium receptor antagonism. When the compound of the present invention is used as a therapeutic agent for osteoporosis, hypothyroidism, osteosarcoma, periodontal disease, fracture, deformable arthrosis, chronic joint rheumatism, Paget's disease, liquid hypercalcemia, autosomal dominant hypocalcemia, etc. Topical administration is oral or parenteral.
[359] The dosage varies depending on age, weight, symptoms, therapeutic effect, administration method, treatment time and the like, but is usually orally or parenterally administered once to several times per day in the range of 0.01 mg to 10 g per adult.
[360] When the compound of the present invention is used as a solid composition for oral administration, it is possible to formulate tablets, pills, powders, granules and the like. In such solid compositions one or more active substances are at least one inert diluent, dispersant or adsorbent, such as lactose, mannitol, glucose, hydroxypropylcellulose, crystalline cellulose, starch, polyvinylhydrin, metasilicate alu It is mixed with magnesium carbonate or anhydrous silicate. Moreover, the composition may mix additives other than a diluent in accordance with a conventional method.
[361] When manufacturing with tablets or pills, you may coat with the film of gastric or enteric substance, such as a white sugar, gelatin, hydroxypropyl cellulose, or hydroxymethyl cellulose phthalate, and may coat with two or more layers as needed. It may also be a capsule of a substance such as gelatin or ethyl cellulose.
[362] In the case of a liquid composition for oral administration, formulations such as pharmaceutically acceptable emulsions, solubilizers, suspensions, syrups or elixirs are possible. Diluents to be used include, for example, purified water, ethanol, vegetable oil or emulsifier. In addition to the diluent, the composition may also contain auxiliaries such as wetting agents, suspending agents, sweetening agents, flavoring agents, fragrances or preservatives.
[363] When prepared as a parenteral injection, a sterile aqueous or nonaqueous solution, solubilizer, suspending agent or emulsifier is used. Aqueous solutions, solubilizers and suspending agents include, for example, distilled water for injection, physiological saline cyclodextrin and derivatives thereof, organic amines such as triethanolamine, diethanolamine, monoethanolamine, triethylamine, and inorganic alkaline solutions.
[364] When using as a water-soluble solution, you may use vegetable oils, such as propylene glycol, polyethyleneglycol, or olive oil, alcohols, such as ethanol, etc., for example. As the solubilizer, for example, surfactants such as polyoxyethylene hydrogenated castor oil and sucrose fatty acid ester (mixed micelle formation), lecithin or hydrogenated lecithin (ribosome formation) and the like are also used. Moreover, it can also be set as the emulsion formulation which consists of water-insoluble dissolving agents, such as vegetable oil, lecithin, polyoxyethylene hardened castor oil, polyoxyethylene polyoxypropylene glycol, etc.
[365] Other compositions for parenteral administration may include external solutions, coatings such as ointments, suppositories or pessaries, which contain one or more active substances and are administered in a manner known per se.
[162] MEANS TO SOLVE THE PROBLEM As a result of earnestly researching in order to solve the said subject, the present inventors discovered that the compound represented by following formula [1] has the outstanding calcium receptor antagonism, and was oral and intermittent administration, and completed this invention. All of the known calcium receptor antagonists continuously raise blood PTH concentrations, and thus, sufficient bone formation promoting action could not be expected. On the other hand, the compound represented by the following formula can surprisingly raise blood PTH concentration non-continuously and intermittently, and can expect great utility as an excellent osteoporosis therapeutic drug.
[163] Compounds represented by the following formulas related to the present invention have a carbon atom adjacent to an oxygen atom having R ¹ and R ² as substituents, ie
[164]
[165] It is characterized by having a structure of. As is apparent from the test examples described later,
[166]
[167] The present invention compound having the structure of not only has excellent calcium receptor antagonism,
[168]
[169] Non-continuously compared with the conventional compound of the structure of having a transient PTH secretion promoting action. Therefore, by administering the compound of the present invention, the same effect as in the case of intermittent administration of PTH can be obtained, and it is considered to be very effective for the treatment of osteoporosis.
[170] Therefore, the present invention relates to a compound represented by the following formula, a calcium receptor antagonist and osteoporosis therapeutic drug using the compound as an active ingredient, and an intermediate compound useful for synthesizing these compounds. In more detail, it is as showing to following (1)-(21).
[171] (1) Formula [I]
[172]
[173] [Wherein, R ¹ is an aryl group or a heteroaryl group (this aryl group and heteroaryl group is a halogen atom, a C _1-6 alkyl group, a halo (C _1-6 ) alkyl group, a hydroxy (C _1-6 ) alkyl group, C _1-6 alkoxycarbonyl (C _1-6) alkyl group, a hydroxyl group, C _1-6 alkoxy groups, halo (C _1-6) alkoxy group, a mercapto group, C _1-6 alkylthio, C _1-6 alkyl sulfanyl group , C _1-6 alkylsulfonyl group, aminosulfonyl group, C _1-6 alkylsulfamoyl group, di (C _1-6 ) alkylsulfamoyl group, carboxyl group, (C _1-6 alkoxy) carbonyl group, C _1-7 ah Real group, carbamoyl group, (C _1-6 alkyl) carbamoyl group, di (C _1-6 alkyl) carbamoyl group, cyano group, nitro group, amino group, C _1-6 alkylamino group, di (C _1-6 ) Alkylamino group, C _1-7 acylamino group, C _1-3 alkylenedioxy group,
[174]
[175] It may be substituted with 1 to 3 substituents selected from (wherein R ^A is (C _1-6 alkoxy) represents a carbonyl group or carboxyl group, R ^B represents a hydrogen atom or a C _1-6 alkyl group)} represents;
[176] R ² is a C _1-6 alkyl group (this C _1-6 alkyl group is a halogen atom, hydroxyl group, C _1-6 alkoxy group, carboxyl group, amino group, C _1-6 alkylamino group, di (C _1-6 ) alkylamino group and oxo It may be substituted with 1 to 3 substituents selected from the group), C _3-7 cycloalkyl group, C _2-6 alkenyl group, C _2-6 alkynyl group, aralkyl group, carboxyl group, (C _1-6 alkoxy) carbonyl group Or a cyano group;
[177] R ³ is a hydrogen atom, C _1-6 alkyl group, hydroxyl group, C _1-6 alkoxy group, mercapto group, C _1-6 alkylthio group, carboxyl group, (C _1-6 alkoxy) carbonyl group, (C _1-6 alkyl ) Carbamoyl group, di (C _1-6 alkyl) carbamoyl group, amino group, C _1-6 alkylamino group or di (C _1-6 ) alkylamino group;
[178] R ⁴ represents a hydrogen atom, a C _1-6 alkyl group or a C _2-6 alkenyl group, or R ³ and R ⁴ are monovalent to represent an oxo group;
[179] R ⁵ and R ⁶ each represent the same or differently a C _1-6 alkyl group, or R ⁵ and R ⁶ are integrated to represent a cyclopropyl group together with the carbon atom to which they are bonded;
[180] R ⁷ is an aryl group or heteroaryl group (This aryl group and heteroaryl group is a halogen atom, C _1-6 alkyl group, halo (C _1-6 ) alkyl group, hydroxy (C _1-6 ) alkyl group, C _3-7 cyclo Alkyl group, hydroxyl group, C _1-6 alkoxy group, halo (C _1-6 ) alkoxy group, carboxyl group, (C _1-6 alkoxy) carbonyl group, nitro group, cyano group, C _1-6 alkylsulfonyloxy group, carbamoyl group And may be substituted with 1 to 3 substituents selected from C _1-3 alkylenedioxy group}.
[181] X ¹ represents a single bond, a C _1-6 alkylene group or a C _2-6 alkynylene group (this C _1-6 alkylene group and C _2-6 alkynylene group may be substituted with a C _1-6 alkyl group or an oxo group) Represents;
[182] X ² represents a C _1-6 alkylene group (this C _1-6 alkylene group may be substituted with a C _1-6 alkyl group or a halo (C _1-6 ) alkyl group);
[183] X ³ represents a single bond or a C _1-6 alkylene group (this C _1-6 alkylene group may be substituted with a hydroxyl group or an oxo group);
[184] X ⁴ and X ⁵ are united to form a single bond, methylene group, -NH-, oxygen atom, sulfur atom, -C (= O)-, -CH ₂ NH-, -CH ₂ O-, -CH ₂ S-, _{-CH 2 CO-, -NHCH 2 -,} -OCH 2 -, -SCH 2 -, -COCH 2 -, represents a -CH = CH- or -C≡C-] the compound represented by (the compound [ⅰ] Or salts thereof or solvates thereof or prodrugs thereof.
[185] (2) Formula [I ']
[186]
[187] [Wherein, R ^{1 ′} is an aryl group or a heteroaryl group (this aryl group and heteroaryl group is a halogen atom, a C _1-6 alkyl group, a halo (C _1-6 ) alkyl group, a hydroxy (C _1-6 ) alkyl group, C _1-6 alkoxy (C _1-6) alkyl group, a hydroxyl group, C _1-6 alkoxy groups, halo (C _1-6) alkoxy group, a mercapto group, C _1-6 alkylthio, C _1-6 alkyl sulfanyl Nyl group, C _1-6 alkylsulfonyl group, aminosulfonyl group, C _1-6 alkylsulfamoyl group, di (C _1-6 ) alkylsulfamoyl group, carboxyl group, (C _1-6 alkoxy) carbonyl group, C _1-7 Acyl group, carbamoyl group, (C _1-6 alkyl) carbamoyl group, di (C _1-6 alkyl) carbamoyl group, cyano group, nitro group, amino group, C _1-6 alkylamino group, di (C _{1- 6} ) may be substituted with 1 to 3 substituents selected from an alkylamino group and a C _1-7 acylamino group;
[188] R ^{7 '} is an aryl group or heteroaryl group {This aryl group and heteroaryl group are halogen atoms, C _1-6 alkyl group, halo (C _1-6 ) alkyl group, C _3-6 cycloalkyl group, hydroxyl group, C _1-6 alkoxy It may be substituted with 1 to 3 substituents selected from the group, halo (C _1-6 ) alkoxy group, carboxyl group, (C _1-6 alkoxy) carbonyl group, nitro group, cyano group and C _1-6 alkylsulfonyloxy group. };
[189] R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , X ¹ , X ² , X ³ , X ⁴ and X ⁵ are the same as in the above (1)] (hereinafter compound [I '] Or its salt or solvate thereof or its prodrug.
[190] (3) Formula [I "]
[191]
[192] [Wherein, R ^{1 ″} represents an aryl group or a heteroaryl group (this aryl group and heteroaryl group are C _1-3 alkylenedioxy group,
[193]
[194] It may be substituted with 1 to 3 substituents selected from (wherein R ^A is (C _1-6 alkoxy) represents a carbonyl group or carboxyl group, R ^B represents a hydrogen atom or a C _1-6 alkyl group)} represents;
[195] R ^{7 "} is an aryl group or heteroaryl group (this aryl group and heteroaryl group may be substituted with 1 to 3 substituents selected from hydroxy (C _1-6 ) alkyl group, carbamoyl group and C _1-3 alkylenedioxy May be used;
[196] R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , X ¹ , X ² , X ³ , X ⁴ and X ⁵ are the same as in the above (1)] (hereinafter compound [I "] Or its salt or solvate thereof or its prodrug.
[197] (4) Chemical Formula [I-2]
[198]
[199] [Wherein, R ¹¹ and R ¹² are the same or different and each is a hydrogen atom, a halogen atom, a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, A hydroxyl group, a C _1-4 alkoxy group, a cyano group, or a nitro group, or R ¹¹ and R ¹² are integrated to represent a C _1-3 alkylenedioxy group, and R ²¹ is a C _1-4 alkyl group (this alkyl group is C _May be substituted with a _1-4 alkoxy group), a C _3-5 cycloalkyl group, a C _2-4 alkenyl group or an aralkyl group, and R ³ , R ⁴ , R ⁵ , R ⁶ , R ⁷ , X ¹ , X ² , X ³ , X ⁴ and X ⁵ are the same as in (1), respectively) (hereinafter sometimes abbreviated as compound [I-2]), a salt thereof or a solvate thereof or a prodrug thereof.
[200] (5) Chemical Formula [I-3]
[201]
[202] Wherein R ⁷¹ and R ⁷² are the same or different and each represents a hydrogen atom, a C _1-4 alkyl group or a C _1-4 alkoxy group, or are integral with -CH = CH-CH = CH- or C _1-3 A compound of the above (4) (hereinafter sometimes abbreviated as Compound [I-3]) represented by an alkylenedioxy group, wherein R ¹¹ , R ¹² and R ²¹ are the same as in (4) above, or a salt thereof The solvate or the prodrug thereof.
[203] (6) R ¹¹ and R ¹² are the same or different, and each represents a hydrogen atom, a chlorine atom, a methyl group, a hydroxymethyl group, a hydroxyl group, a methoxy group, a cyano group, or a nitro group, or R ¹¹ and R ¹² are integral with methylene A compound of the above (5), a salt thereof, or a solvate thereof, or a prodrug thereof, which represents a deoxy group and R ²¹ is a C _1-4 alkyl group or C _3-5 cycloalkyl group which may be branched.
[204] (7) The compound of the above (6), a salt thereof, or a solvate thereof, or a prodrug thereof, wherein R ²¹ is a methyl group, an ethyl group, a cyclopropyl group, or a cyclobutyl group.
[205] (8) The above (7) wherein R ¹¹ is a hydrogen atom, R ¹² is a methyl group, a methoxy group or a hydroxymethyl group, or R ¹¹ and R ¹² are united to represent a methylenedioxy group, and R ²¹ is a methyl group or a cyclopropyl group; ), Salts thereof or solvates thereof or prodrugs thereof.
[206] (9) The compound of the above (8), a salt thereof, or a solvate thereof, or a prodrug thereof, wherein R ²¹ is a cyclopropyl group.
[207] (10) The compound of the above (9), a salt thereof, or a solvate thereof, or a prodrug thereof, wherein R ⁷¹ and R ⁷² are integrated to represent -CH = CH-CH = CH-.
[208] (11) The compound of the above (9), a salt thereof, or a solvate thereof or a prodrug thereof, wherein R ⁷¹ and R ⁷² are a group selected from a C _1-4 alkyl group and a C _1-4 alkoxy group.
[209] (12)
[210] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methoxyphenyl) methoxy] propan-2-ol,
[211] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methylphenyl) methoxy] propan-2-ol,
[212] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (phenyl) methoxy] propan-2-ol,
[213] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) ethoxy] propan-2-ol,
[214] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methylphenyl) ethoxy] propan-2-ol,
[215] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) propoxy] propan-2-ol,
[216] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-cyanophenyl) ethoxy] propan-2-ol,
[217] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (3-methoxyphenyl) ethoxy] propan-2-ol and
[218] The above (1) selected from (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (3-methylphenyl) ethoxy] propan-2-ol ), Salts thereof or solvates thereof or prodrugs thereof.
[219] (13) (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-hydroxymethylphenyl) methoxy] propane-2- Ol, its salt or solvate or its prodrug.
[220] (14) A pharmaceutical composition comprising, as an active ingredient, any one of the compounds (1) to (13), a salt thereof, a solvate thereof, or a prodrug thereof.
[221] (15) A calcium receptor antagonist comprising the compound of any one of (1) to (13), a salt thereof, a solvate thereof, or a prodrug thereof as an active ingredient.
[222] (16) A therapeutic agent for osteoporosis, comprising any of the compounds (1) to (13) above, a salt thereof, a solvate thereof, or a prodrug thereof as an active ingredient.
[223] (17) Formula [II]
[224]
[225] [Wherein, R ^{11 ′} is a halogen atom, a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, a hydroxyl group, a C _1-4 alkoxy group, tert Butyldimethylsilyloxymethyl group, cyano group or nitro group] (hereinafter sometimes abbreviated as compound [II]) or a salt thereof or solvate thereof.
[226] (18) The compound of the above (17) or a salt or solvate thereof, wherein R ^{11 '} in the formula [II] is a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group or a C _1-4 alkoxy group.
[227] (19) Formula [III]
[228]
[229] [Wherein, R ^{11 "} is a halogen atom, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, a hydroxyl group, a C _1-4 alkoxy group, tert-butyldimethylsilyloxymethyl group , Cyano group or nitro group] (hereinafter sometimes abbreviated as compound [III]) or a salt thereof or solvate thereof.
[230] (20) The compound of the above (19), or a salt thereof or a solvate thereof, wherein in Formula [III], R ^{11 "} is a C _1-4 alkoxy group.
[231] (21) Formula [IV]
[232]
[233] Wherein R ⁸ represents a carboxyl group, nitro group, tert-butoxycarbonylamino group or benzyloxycarbonylamino group (hereinafter sometimes abbreviated as compound [IV]) or a salt thereof or solvate thereof .
[366] The compound represented by general formula [I] which concerns on this invention, and its manufacturing method are demonstrated concretely according to the following Example. However, the present invention is of course not limited to these examples.
[367] Example 1
[368] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methoxyphenyl) methoxy] propan-2-ol
[369] Process 1
[370] (Cyclopropyl) (2-methoxyphenyl) methanol
[371]
[372] Magnesium (10.7 g) was dissolved in tetrahydrofuran (80 mL) and iodine (5 mg) was added. Bromocyclopropane (32.0 ml) was added dropwise thereto for 1.5 hours, and then heated to reflux for 1.5 hours. Tetrahydrofuran was added here to make 1M brominated cyclopropylmagnesium-tetrahydrofuran solution. Subsequently, o-anisaldehyde (8.17 g) was dissolved in tetrahydrofuran (150 mL), 1M brominated cyclopropylmagnesium-tetrahydrofuran solution (90 mL) was added dropwise under ice cooling for 50 minutes, and stirred at room temperature for 12 hours. It was. The reaction solution was ice-cooled and saturated aqueous ammonium chloride solution (9 mL) was added, followed by stirring at room temperature for 30 minutes. The organic layer was dried over magnesium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (n-hexane: ethyl acetate = 9: 1) to obtain the title compound (6.13 g).
[373] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.41 (1H, d, J = 7.8 Hz), 7.19 (1H, dt, J = 1.6,7.7 Hz), 6.92 (2H, t, J = 7.2 Hz ), 4.88 (1H, d, J = 4.8 Hz), 4.55 (1H, t, J = 5.5 Hz), 3.76 (3H, s), 1.09-1.00 (1H, m), 0.33-0.25 (4H, m) .
[374] MS (ESI, m / z) 161 (M + H−H ₂ O) ⁺ .
[375] Process 2
[376] (R) -2-[(cyclopropyl) (2-methoxyphenyl) methoxymethyl] oxirane
[377]
[378] (Cyclopropyl) (2-methoxyphenyl) methanol (3.57 g) obtained in step 1 was dissolved in N, N-dimethylformamide (50 mL), and sodium hydride (960 mg, 60% oil) was added to Stirred for a minute. Then (R) -glycidyl 3-nitrobenzenesulfonate (6.22 g) was added and stirred at room temperature for 12 hours. The reaction mixture was poured into water and extracted with diethyl ether. The organic layer was washed with water and saturated aqueous sodium chloride solution in that order, dried over sodium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (n-hexane: ethyl acetate = 88: 12) to obtain the title compound (1.10 g). Got.
[379] Process 3
[380] 2-methyl-1- (naphthalen-2-yl) -2-nitropropanol
[381]
[382] Tetrahydrofuran (20 ml) was added to tetrabutylammonium fluoride trihydrate (2.41 g) and ice-cooled. 2-nitropropane (2.7 mL), 2-naphthaldehyde (3.12 g) and triethylamine (2.8 mL) were added under argon atmosphere. A tetrahydrofuran (20 mL) solution of tert-butyldimethylchlorosilane (4.51 g) was further added, and the mixture was stirred for 40 minutes while returning to room temperature under ice cooling. The insolubles were filtered off, and the filtrate was poured into a diethylether: n-hexane = 1: 3 solution (500 mL) and washed twice with water (40 mL). The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue obtained was crystallized with n-hexane to obtain the title compound (3.78 g).
[383] Process 4
[384] 2- (1-chloro-2-methyl-2-nitropropyl) naphthalene
[385]
[386] Thionyl chloride (3.1 ml) is added to 2-methyl-1- (naphthalen-2-yl) -2-nitropropanol (1.23 g) obtained in step 3, followed by heating to reflux for 1 hour, followed by room temperature for 12 hours. Stirred at. The residue obtained by concentrating the reaction solution under reduced pressure was poured into water and extracted with ethyl acetate. The organic layer was washed with water, saturated aqueous sodium hydrogen carbonate solution in that order, dried over anhydrous sodium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (n-hexane: ethyl acetate = 93: 7). The result was recrystallized from a n-hexane: ethyl acetate = 4: 1 solution, and the title compound (776 mg) was obtained.
[387] Process 5
[388] 2- (2-methyl-2-nitropropyl) naphthalene
[389]
[390] 2- (1-chloro-2-methyl-2-nitropropyl) naphthalene (200 mg) obtained in step 4 was dissolved in methanol (5 mL) and ethyl acetate (5 mL), and 10% palladium carbon (200 mg) Was added and hydrogenated at 3 atmospheres for 2 hours. The reaction solution was filtered through Celite, and purified by silica gel column chromatography (n-hexane: ethyl acetate = 95: 5) to obtain the title compound (139 mg).
[391] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.85-7.76 (3H, m), 7.58 (1H, s), 7.50-7.44 (2H, m), 7.22 (1H, dd, J = 1.7, 8.4 Hz) , 3.37 (2H, s), 1.69 (6H, s).
[392] MS (APCI, m / z) 183 (M + H-NO ₂ ) ⁺ .
[393] Process 6
[394] [2-methyl-1- (naphthalen-2-yl) propan-2-yl] amine
[395]
[396] Raney nickel W2 (200 mg) was suspended in ethanol (10 mL), and 2- (2-methyl-2-nitropropyl) naphthalene (134 mg) obtained in step 5 was added to hydrogenate at 3.5 atmospheres for 12 hours. Was carried out. The reaction solution was filtered through Celite, and the residue obtained by concentration under reduced pressure was crystallized with ethyl acetate to obtain the title compound (70 mg).
[397] Process 7
[398] 2-methyl-1- (naphthalen-2-yl) -2-propanol
[399]
[400] 2-methylnaphthalene (7.11 g) was dissolved in tetrahydrofuran (100 mL), cooled to -69 ° C and 1.6M n-butyllithium-tetrahydrofuran solution (34 mL) was added dropwise. Then, a solution of acetone (4.41 ml) of tetrahydrofuran (4.41 ml) was added dropwise and stirred for 12 hours while returning to room temperature. Saturated ammonium chloride solution (6 mL) was added dropwise to the reaction solution, which was then poured into water (200 mL) and extracted with diethyl ether. The organic layer was washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 85:15) to obtain the title compound (3.80 g).
[401] Process 8
[402] N- [2-methyl-1- (naphthalen-2-yl) propan-2-yl] acetamide
[403]
[404] Acetonitrile (0.5 mL) and acetic acid (0.5 mL) were sequentially added to 2-methyl-1- (naphthalen-2-yl) -2-propanol (500 mg) obtained in step 7, followed by ice cooling. Ml) was added dropwise. After stirring for 20 minutes under ice cooling, the mixture was poured into 1N aqueous sodium hydroxide solution and extracted with diethyl ether. The organic layer was washed with water, dried over sodium sulfate, and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate-n-hexane to obtain the title compound (303 mg).
[405] Process 9
[406] [2-methyl-1- (naphthalen-2-yl) propan-2-yl] amine
[407]
[408] 6N hydrochloric acid (2 ml) was added to N- [2-methyl-1- (naphthalen-2-yl) propan-2-yl] acetamide (26 mg) obtained in Step 8, and the mixture was heated to reflux for 5 hours. The reaction solution was poured into water, made basic with 4N aqueous sodium hydroxide solution, and extracted with diethyl ether. The organic layer was washed with water, dried over potassium carbonate and concentrated under reduced pressure to obtain the title compound (19 mg).
[409] Process 10
[410] 2,2-dimethyl-3- (naphthalen-2-yl) propionic acid
[411]
[412] A tetrahydrofuran (3.5 L) solution of diisopropylamine (576 mL) was cooled to -68 ° C and 2.6M n-butyllithium-n-hexane solution (1.5 L) was added slowly under argon atmosphere. Subsequently, a hexamethylphosphoamide (340 ml) solution of isobutyric acid (181 ml) was added dropwise, followed by stirring at room temperature for 30 minutes. After ice-cooling, a tetrahydrofuran (1 L) solution of 2-bromomethylnaphthalene (392 g) was added dropwise and stirred at room temperature for one day. The reaction solution was ice-cooled and 6N hydrochloric acid (665 mL) was added to separate an organic layer and an aqueous layer. The separated organic layer was concentrated under reduced pressure to give a residue. On the other hand, ethyl acetate and water were added to the aqueous layer to separate the aqueous layer and the organic layer. The organic layer and the residue were washed together with water three times. A water (600 mL) solution of sodium hydroxide (80 g) was added to the organic layer, followed by extraction three times with 4N aqueous sodium hydroxide solution (200 mL). The aqueous layer was washed with ethyl acetate, acidified by addition of concentrated hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with an aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the title compound (177.5 g).
[413] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.88-7.80 (3H, m), 7.66 (1H, s), 7.51-7.44 (2H, m), 7.33 (1H, dd, J = 8.4, 1.6 Hz), 2.96 (2H, s), 1.13 (6H, s).
[414] MS (FAB, m / z) 228 (M) ⁺ .
[415] Process 11
[416] N- [2-methyl-1- (naphthalen-2-yl) propan-2-yl] -benzyloxycarboxamide
[417]
[418] 2,2-dimethyl-3- (naphthalen-2-yl) propionic acid (205.4 g) obtained in step 10 was dissolved in water (173 mL), triethylamine (131 mL) and acetone (800 mL), and Acetone (400 mL) solution of ethyl chlorocarbonate (101.5 mL) was added. Then, a water (400 mL) solution of sodium azide (73.1 g) was added dropwise and stirred at room temperature for 2 hours. Water (1.5 L) and toluene (1.2 L) were added to the reaction solution to separate an organic layer and an aqueous layer. The organic layer was washed twice with water and three times with saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. After filtration of the desiccant, the filtrate was heated to 100 ° C. for 4 hours under argon atmosphere and stirred at 100 ° C. for 1 hour. The reaction solution was concentrated under reduced pressure, benzyl alcohol (500 mL) was added, and the mixture was stirred at 105 ° C for one day. The reaction solution was concentrated under reduced pressure, and ethyl acetate and n-hexane were added to the residue, which was then treated with activated carbon. Then, the residue obtained by concentrating under reduced pressure was purified by silica gel column chromatography (n-hexane: ethyl acetate = 20: 1) to obtain the title compound (240.5 g).
[419] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 8.83-7.78 (1H, m), 7.71-7.66 (2H, m), 7.45-7.36 (7H, m), 7.22 (1H, dd, J = 1.6, 8.4 Hz), 5.13 (2H, s), 4.54 (1H, br s), 3.15 (2H, s), 1.34 (6H, s).
[420] MS (FAB, m / z) 334 (M + H) ⁺ .
[421] Process 12
[422] [2-methyl-1- (naphthalen-2-yl) propan-2-yl] amine
[423]
[424] Palladium hydroxide (19.7 g) was suspended in methanol (500 mL), and N- [2-methyl-1- (naphthalen-2-yl) propan-2-yl] -benzyloxycarboxamide ( A solution of 237.6 g) of methanol (2 L) was added to carry out hydrogenation overnight at room temperature. The reaction solution was filtrated, ethyl acetate was added to the residue obtained by concentrating the filtrate under reduced pressure to make a solution, and concentrated hydrochloric acid (70 mL) was added thereto to obtain crystals. The obtained crystals were suspended in water, and 4N aqueous sodium hydroxide solution (350 ml) was added, followed by extraction with ethyl acetate. Ethyl acetate was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the title compound (138 g).
[425] Process 13
[426] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methoxyphenyl) methoxy] propan-2-ol
[427]
[428] (R) -2-[(cyclopropyl) (2-methoxyphenyl) methoxymethyl] oxirane (703 mg) obtained in Step 2 was dissolved in ethanol (12 mL), Step 6, Step 9 or Step 12 [2-methyl-1- (naphthalen-2-yl) propan-2-yl] amine (120 mL) was added and stirred at 60 ° C. for 20 hours. The residue obtained by concentrating the reaction solution under reduced pressure was purified by silica gel column chromatography (chloroform: methanol = 97: 3) to obtain the title compound (954 mg).
[429] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.90-7.70 (3H, m), 7.67 (1H, s), 7.50-7.20 (5H, m) 7.00-6.90 (2H, m), 4.62 (1H , br s), 4.29 (1H, d, J = 7.0 Hz), 3.77 (3H, s), 3.70-3.50 (1H, m), 3.30-3.10 (2H, m), 2.80-2.50 (4H, m) , 1.50-0.85 (8H, m), 0.50-0.20 (4H, m).
[430] MS (APCI, m / z) 433 (M + H) ⁺ .
[431] Example 2
[432] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methylphenyl) methoxy] propan-2-ol
[433] Process 1
[434] (Cyclopropyl) (2-methylphenyl) methanol
[435]
[436] In the same manner as in Process 1 of Example 1, o-tolualdehyde (4.81 g) was used instead of o-anisaldehyde to obtain the title compound (5.36 g).
[437] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.43 (1H, d, J = 7.2 Hz), 7.18-7.10 (3H, m), 4.95 (1H, d, J = 4.8 Hz), 4.36 (1H , dd, J = 4.4, 6.5 Hz), 2.31 (3H, s), 1.20-1.07 (1H, m), 0.47-0.20 (4H, m).
[438] MS (APCI, m / z) 145 (M + HH ₂ O) ⁺ .
[439] Process 2
[440] (R) -2-[(cyclopropyl) (2-methylphenyl) methoxymethyl] oxirane
[441]
[442] The title compound (1.53g) was obtained in the same manner as in Step 2 of Example 1 from (cyclopropyl) (2-methylphenyl) methanol (3.25g) obtained in Step 1.
[443] Process 3
[444] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methylphenyl) methoxy] propan-2-ol
[445]
[446] The title compound (849 mg) was obtained in the same manner as in Step 13 of Example 1 from (R) -2-[(cyclopropyl) (2-methylphenyl) methoxymethyl] oxirane (655 mg) obtained in Step 2.
[447] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.90-7.70 (3H, m), 7.67 (1H, s), 7.50-7.25 (4H, m) 7.20-7.10 (3H, m), 4.65 (1H , br s), 4.06 (1H, d, J = 7.4Hz), 3.70-3.50 (1H, m), 3.30-3.10 (2H, m), 2.80-2.50 (4H, m), 2.31 (3H, s) , 1.50-0.80 (8H, m), 0.60-0.10 (4H, m).
[448] MS (APCI, m / z) 417 (M + H) ⁺ .
[449] Example 3
[450] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (phenyl) methoxy] propan-2-ol
[451] Process 1
[452] (R) -2-[(cyclopropyl) (phenyl) methoxymethyl] oxirane
[453]
[454] The title compound (296 mg) was obtained from α-cyclopropyl benzyl alcohol (740 mg) in the same manner as in Step 2 of Example 1.
[455] Process 2
[456] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (phenyl) methoxy] propan-2-ol
[457]
[458] The title compound (334 mg) was obtained in the same manner as in Step 13 of Example 1 from (R) -2-[(cyclopropyl) (phenyl) methoxymethyl] oxirane (204 mg) obtained in Step 1.
[459] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.90-7.70 (3H, m), 7.67 (1H, s), 7.50-7.20 (8H, m) 4.65 (1H, br s), 3.80-3.50 ( 2H, m), 3.30-3.10 (2H, m), 2.80-2.50 (4H, m), 1.50-0.80 (8H, m), 0.60-0.10 (4H, m).
[460] MS (APCI, m / z) 403 (M + H) ⁺ .
[461] Example 4
[462] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) ethoxy] propan-2-ol
[463] Process 1
[464] 1- (2-methoxyphenyl) ethanol
[465]
[466] Lithium aluminum hydride (1.52 g) was suspended in tetrahydrofuran (100 mL), 2'-methoxyacetophenone (2.76 mL) was added under ice cooling, and stirred for 30 minutes. Water (1.5 mL), 15% aqueous sodium hydroxide solution (1.5 mL), and water (4.5 mL) were added to the reaction solution in that order. The organic layer was dried over magnesium sulfate, and concentrated under reduced pressure to obtain the title compound (3.05 g).
[467] Process 2
[468] (R) -2- [1- (2-methoxyphenyl) ethoxymethyl] oxirane
[469]
[470] The title compound (123 mg) was obtained in the same manner as in Step 2 of Example 1 from 1- (2-methoxyphenyl) ethanol (837 mg) obtained in Step 1.
[471] Process 3
[472] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) ethoxy] propan-2-ol
[473]
[474] The title compound (148 mg) was obtained in the same manner as in Step 13 of Example 1 from (R) -2- [1- (2-methoxyphenyl) ethoxymethyl] oxirane (115 mg) obtained in Step 2.
[475] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.85-7.70 (3H, m), 7.61 (1H, s), 7.50-7.20 (5H, m), 7.00-6.80 (2H, m), 4.88 ( 1H, q, J = 6.4 Hz), 3.85-3.75 (4H, m), 3.45-3.35 (2H, m), 2.85-2.60 (4H, m), 1.40-1.37 (3H, m), 1.10-1.08 ( 6H, m).
[476] MS (APCI, m / z) 408 (M + H) ⁺ .
[477] Example 5
[478] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) ethoxy] propan-2-ol hydrochloride
[479]
[480] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) ethoxy] propane-2- obtained in Example 4 Ol (141 mg) was dissolved in diethyl ether (5 mL) and 4N hydrogen chloride-ethyl acetate solution was added. The reaction solution was concentrated under reduced pressure, diethyl ether (5 ml) was added, and the residue was concentrated under reduced pressure to obtain the title compound (154 mg).
[481] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 8.91 (1 H, br s), 8.54 (1 H, br s), 7.95-7.86 (3H, m), 7.67 (1 H, s), 7.55-7.45 ( 2H, m), 7.40-7.20 (3H, m), 7.02-6.93 (2H, m), 5.66-5.61 (1H, m), 4.90-4.80 (1H, m), 4.05-3.95 (1H, m), 3.80 (3H, s), 3.40-3.10 (5H, m), 3.05-2.85 (1H, m), 1.32 (3H, d, J = 6.4 Hz), 1.09 (6H, s).
[482] MS (APCI, m / z) 408 (M + H-HCl) ⁺ .
[483] Example 6
[484] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methylphenyl) ethoxy] propan-2-ol
[485] Process 1
[486] 1- (2-methylphenyl) ethanol
[487]
[488] The title compound (755 mg) was obtained from 2'-methylacetophenone (2.68 g) in the same manner as in Step 1 of Example 4.
[489] Process 2
[490] (R) -2- [1- (2-methylphenyl) ethoxymethyl] oxirane
[491]
[492] The title compound (123 mg) was obtained in the same manner as in Step 2 of Example 1 from 1- (2-methylphenyl) ethanol (749 mg) obtained in Step 1.
[493] Process 3
[494] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methylphenyl) ethoxy] propan-2-ol
[495]
[496] The title compound (345 mg) was obtained in the same manner as in Step 13 of Example 1 from (R) -2- [1- (2-methylphenyl) ethoxymethyl] oxirane (192 mg) obtained in Step 2.
[497] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.85-7.70 (3H, m), 7.60 (1H, s), 7.50-7.10 (7H, m), 4.75-4.65 (1H, m), 3.80-3.70 ( 1H, m), 3.40-3.30 (2H, m), 2.90-2.60 (4H, m), 2.31 (3H, s), 1.39 (3H, d, J = 6.4 Hz), 1.10-1.07 (6H, m) .
[498] MS (APCI, m / z) 392 (M + H) ⁺ .
[499] Example 7
[500] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methylphenyl) ethoxy] propan-2-ol hydrochloride
[501]
[502] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methylphenyl) ethoxy] propan-2-ol obtained in Example 6 ( 339 mg) was obtained in the same manner as in Example 5 to obtain the title compound (337 mg).
[503] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 8.97 (1 H, br s), 8.56 (1 H, br s), 7.95-7.85 (3 H, m), 7.77 (1 H, s), 7.75-7.65 ( 2H, m), 7.40-7.32 (2H, m), 7.25-7.12 (3H, m), 5.66-5.61 (1H, m), 4.73 (1H, q, J = 6.3 Hz), 4.10-3.95 (1H, br s), 3.40-3.10 (5H, m), 3.05-2.90 (1H, m), 2.31 (3H, s), 1.34 (3H, d, J = 6.6 Hz), 1.27 (3H, s), 1.26 ( 3H, s).
[504] MS (APCI, m / z) 392 (M + H-HCl) ⁺ .
[505] Example 8
[506] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) propoxy] propan-2-ol
[507] Process 1
[508] 1- (2-methoxyphenyl) propanol
[509]
[510] o-anisaldehyde (2.72 g) was dissolved in tetrahydrofuran (50 mL), and 0.93M ethylmagnesium bromide-tetrahydrofuran solution (31.3 mL) was added dropwise under ice cooling for 10 minutes, and stirred at room temperature for 2 hours. The reaction solution was ice-cooled, and saturated aqueous ammonium chloride solution (40 mL) and water (40 mL) were added, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (n-hexane: ethyl acetate = 4: 1) to obtain the title compound (3.15 g). .
[511] Process 2
[512] (R) -2- [1- (2-methoxyphenyl) propoxymethyl] oxirane
[513]
[514] The title compound (264 mg) was obtained in the same manner as in Step 2 of Example 1 from 1- (2-methoxyphenyl) propanol (831 mg) obtained in Step 1.
[515] Process 3
[516] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) propoxy] propan-2-ol
[517]
[518] The title compound (403 mg) was obtained in the same manner as in Step 13 of Example 1 from (R) -2- [1- (2-methoxyphenyl) propoxymethyl] oxirane (264 mg) obtained in Step 2.
[519] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.85-7.70 (3H, m), 7.61 (1H, s), 7.50-7.20 (5H, m), 7.00-6.90 (1H, m), 6.85-6.75 ( 1H, m), 4.67 (1H, t, J = 6.3 Hz), 3.85-3.70 (4H, m), 3.42-3.27 (2H, m), 2.90-2.65 (6H, m), 1.15-1.05 (6H, m), 0.91 (3H, t, J = 7.4 Hz).
[520] MS (APCI, m / z) 422 (M + H) ⁺ .
[521] Example 9- Example 20
[522] In the same manner as in Examples 1 to 8, the compounds of Examples 9 to 20 were obtained. These are shown in Table 1 and Table 2.
[523] TABLE 1
[524]
[525] TABLE 2
[526]
[527] Example 21
[528] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R) -1- (2-methoxyphenyl) ethoxy] propan-2-ol
[529] Process 1
[530] (R) -1- (2-methoxyphenyl) ethanol
[531]
[532] 2'-methoxyacetophenone (10.5g) was dripped at the tetrahydrofuran (50 mL) solution of (+)-B-chloro diisopine camphor borane (10.5g) at -25 degreeC. After stirring at −25 ° C. for 1 hour, the reaction solution was concentrated under reduced pressure. Diethyl ether (100 mL) and diethanolamine (18.1 g) were added to the residue, which was stirred at room temperature for 2 hours, after which the precipitated solid was filtered off. The filtrate was concentrated under reduced pressure, and then purified by distillation under reduced pressure (bp 74 to 77 ° C / 1 mmHg) to obtain the title compound (8.00 g).
[533] Process 2
[534] (R) -2-[(1R) -1- (2-methoxyphenyl) ethoxymethyl] oxirane
[535]
[536] The title compound (930 mg) was obtained in the same manner as in Step 2 of Example 1 from (R) -1- (2-methoxyphenyl) ethanol (1.52 g) obtained in Step 1.
[537] Process 3
[538] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R) -1- (2-methoxyphenyl) ethoxy] propan-2-ol
[539]
[540] The title compound (770 mg) from (R) -2-[(1R) -1- (2-methoxyphenyl) ethoxymethyl] oxirane (417 mg) obtained in Step 2 in the same manner as in Step 13 of Example 1 )
[541] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.85-7.70 (3H, m), 7.61 (1H, s), 7.50-7.20 (5H, m), 7.00-6.80 (2H, m), 4.88 (1H, q, J = 6.5 Hz), 3.85-3.75 (4H, m), 3.38 (2H, d, J = 5.1 Hz), 2.90-2.60 (4H, m), 1.38 (3H, d, J = 6.6 Hz), 1.10 (3H, s), 1.07 (3H, s).
[542] MS (APCI, m / z ) 408 (M + H) ⁺ .
[543] Example 22
[544] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R) -1- (2-methoxyphenyl) ethoxy] propan-2-ol Hydrochloride
[545]
[546] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R) -1- (2-methoxyphenyl) ethoxy] obtained in Example 21. The title compound (810 g) was obtained in the same manner as in Example 5 from propan-2-ol.
[547] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 8.94 (1 H, br s), 8.56 (1 H, br s), 7.95-7.85 (3 H, m), 7.77 (1 H, s), 7.57-7.45 ( 2H, m), 7.42-7.20 (3H, m), 7.05-6.95 (2H, m), 5.61 (1H, d, J = 4.8 Hz), 4.84 (1H, q, J = 6.3 Hz), 4.10-3.95 (1H, m), 3.80 (3H, s), 3.40-3.10 (5H, m), 3.00-2.85 (1H, m), 1.32 (3H, d, J = 6.3 Hz), 1.26 (6H, s).
[548] MS (APCI, m / z) 408 (M + H-HCl) ⁺ .
[549] Example 23
[550] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) (2-methylphenyl) methoxy] propan-2-ol
[551] Process 1
[552] N-methoxy-2, N-dimethylbenzamide
[553]
[554] To a dichloromethane (150 mL) solution of o-toluic acid chloride (3.09 g) and triethylamine (5.58 mL), N, O-dimethylhydroxylamine hydrochloride (3.90 g) was added under ice-cooling, at room temperature for 12 hours. Was stirred. The reaction solution was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and washed with 1N hydrochloric acid, water, saturated sodium bicarbonate water and saturated brine in that order. The organic layer was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain the title compound (3.58 g).
[555] Process 2
[556] Cyclopropyl 2-methylphenyl ketone
[557]
[558] To a tetrahydrofuran (40 mL) solution of N-methoxy-2, N-dimethylbenzamide (3.55 g) obtained in Step 1 was added dropwise 1M brominated cyclopropylmagnesium-tetrahydrofuran solution (29.7 mL) under ice cooling, Stir at room temperature for 12 hours. 4N hydrogen chloride-ethyl acetate solution (10 mL) was added to the reaction solution, and the mixture was concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed with 1N hydrochloric acid, water, saturated sodium bicarbonate water and saturated brine in that order, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: hexane = 1: 5) to obtain the title compound (1.05 g).
[559] Process 3
[560] (R)-(cyclopropyl) (2-methylphenyl) methanol
[561]
[562] Dichloro [(S)-(-)-2,2'-bis (diphenylphosphino) -1,1'-binafthyl] ruthenium (II) (851 mg), (1S, 2S)-(-) To the isopropanol (90 mL) suspension of -1,2-diphenylethylenediamine (191 mg) and potassium-tert-butoxide (270 mg) was added cyclopropyl 2-methylphenyl ketone (9.61 g) obtained in step 2, Hydrogen was added (3.0 kgf / cm 2) at medium pressure for 60 hours at room temperature. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate: hexane = 1: 9) to obtain the title compound (6.92 g).
[563] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.43 (1H, d, J = 6.8 Hz), 7.18-7.09 (3H, m), 4.97 (1H, d, J = 4.6 Hz), 4.36 (1H , dd, J = 4.6, 6.4 Hz), 2.30 (3H, s), 1.17-1.07 (1H, m), 0.41-0.24 (4H, m).
[564] MS (APCI, m / z) 145 (M + HH ₂ O) ⁺ .
[565] Process 4
[566] (R) -2-[(1R)-(cyclopropyl) (2-methylphenyl) methoxymethyl] oxirane
[567]
[568] The title compound (1.80g) was obtained in the same manner as in Step 2 of Example 1 from (R)-(cyclopropyl) (2-methylphenyl) methanol (3.24g) obtained in Step 3.
[569] Process 5
[570] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) (2-methylphenyl) methoxy] propan-2-ol
[571]
[572] The title compound (1.17g) from (R) -2-[(1R)-(cyclopropyl) (2-methylphenyl) methoxymethyl] oxirane (655 mg) obtained in Step 4 in the same manner as in Step 13 of Example 1 )
[573] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.90-7.70 (3H, m), 7.66 (1H, s), 7.50-7.25 (4H, m) 7.20-7.10 (3H, m), 4.64 (1H , br s), 4.06 (1H, d, J = 7.4Hz), 3.70-3.50 (1H, m), 3.30-3.10 (2H, m), 2.80-2.50 (4H, m), 2.31 (3H, s) , 1.50-0.85 (2H, m), 0.60-0.10 (4H, m).
[574] MS (APCI, m / z) 417 (M + H) ⁺ .
[575] Example 24
[576] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) (2-methoxyphenyl) methoxy] propane-2 -All
[577] Process 1
[578] 2, N-dimethoxy-N-methylbenzamide
[579]
[580] The title compound (3.56 g) was obtained from 2-methoxybenzoic acid chloride (3.41 g) in the same manner as in Step 1 of Example 23.
[581] Process 2
[582] Cyclopropyl 2-methoxyphenyl ketone
[583]
[584] The title compound (2.27 g) was obtained from the 2, N-dimethoxy-N-methylbenzamide (3.55 g) obtained in Step 1 in the same manner as in Step 2 of Example 23.
[585] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.59 (1H, dd, J = 7.5, 1.7 Hz), 7.48-7.42 (1H, m), 7.02-6.97 (2H, m), 3.91 (3H, s) 2.77-2.68 (1 H, m), 1.25-1.20 (2 H, m), 1.01-0.95 (1 H, m).
[586] MS (ESI, m / z) 177 (M + H) ⁺ .
[587] Process 3
[588] (R)-(cyclopropyl) (2-methoxyphenyl) methanol
[589]
[590] The title compound (3.55g) was obtained from the cyclopropyl 2-methoxyphenyl ketone (3.52g) obtained in the step 2 in the same manner as in the step 3 of Example 23.
[591] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.40 (1H, dd, J = 1.6, 7.5 Hz), 7.26 (1H, dt, J = 1.7,7.8 Hz), 7.00-6.89 (2H, m), 4.20 (1H, br d, J = 8.4 Hz), 3.87 (3H, s), 2.83 (1H, br s), 1.42-1.30 (1H, m), 0.70-0.61 (1H, m), 0.57-0.44 (2H m), 0.37-0.27 (1 H, m).
[592] MS (ESI, m / z) 161 (M + H−H ₂ O) ⁺ .
[593] Process 4
[594] (R) -2-[(1R)-(cyclopropyl) (2-methoxyphenyl) methoxymethyl] oxirane
[595]
[596] The title compound (840 mg) was obtained in the same manner as in Step 2 of Example 1 from (R)-(cyclopropyl) (2-methoxyphenyl) methanol (1.78g) obtained in Step 3.
[597] Process 5
[598] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) (2-methoxyphenyl) methoxy] propane-2 -All
[599]
[600] From (R) -2-[(1R)-(cyclopropyl) (2-methoxyphenyl) methoxymethyl] oxirane (586 mg) obtained in Step 4, the title compound ( 970 mg) was obtained.
[601] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.83-7.70 (3H, m), 7.61 (1H, s), 7.50-7.37 (3H, m), 7.35-7.20 (2H, m), 7.00-6.82 ( 2H, m), 4.28 (1H, d, J = 7.8 Hz), 3.83-3.70 (4H, m), 3.42-3.30 (2H, m), 2.90-2.60 (4H, m), 1.25-1.10 (7H, m), 0.60-0.50 (1H, m), 0.45-0.30 (3H, m).
[602] MS (APCI, m / z) 434 (M + H) ⁺ .
[603] Examples 25-56
[604] In the same manner as in Examples 1 to 24, the compounds of Examples 25 to 56 were obtained. These are shown in Tables 3-7.
[605] TABLE 3
[606]
[607] TABLE 4
[608]
[609] TABLE 5
[610]
[611] TABLE 6
[612]
[613] TABLE 7
[614]
[615] Example 57
[616] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-hydroxymethylphenyl) methoxy] propan-2-ol
[617] Process 1
[618] 2-bromo-1- (tert-butyldimethylsilyloxymethyl) benzene
[619]
[620] 2-bromobenzyl alcohol (25.0 g) was dissolved in N, N-dimethylformamide (150 mL), imidazole (20.0 g) and tert-butyldimethylchlorosilane (22.2 g) were added and 2 hours at room temperature. Was stirred. The reaction solution was poured into 5% aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was washed with 5% aqueous sodium hydrogen carbonate solution, water, and saturated aqueous sodium chloride solution in that order, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain the title compound (40.9 g).
[621] Process 2
[622] (Cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methanol
[623]
[624] Magnesium (2.20 g) was suspended in tetrahydrofuran (4 mL) and iodine (2 mg) was added. A tetrahydrofuran (10 mL) solution of 2-bromo-1- (tert-butyldimethylsilyloxymethyl) benzene (24.0 g) obtained in Step 1 was added dropwise thereto for 30 minutes, and then heated to reflux for 1 hour. Tetrahydrofuran was added here to make 1M 2- (tert-butyldimethylsilyloxymethyl) phenylmagnesium bromide-tetrahydrofuran solution. Then, cyclopropanecarboxyaldehyde (2.80 g) was dissolved in tetrahydrofuran (120 mL), and the 1M 2- (tert-butyldimethylsilyloxymethyl) phenylmagnesium bromide-tetrahydrofuran solution (80 mL) was subjected to ice cooling. 50 minutes was dripped and it stirred at room temperature for 12 hours. A saturated ammonium chloride aqueous solution (8 ml) was added to the reaction solution under ice cooling, and the mixture was stirred at room temperature for 30 minutes. After drying over anhydrous magnesium sulfate, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (n-hexane: ethyl acetate = 95: 5) to obtain the title compound (8.20 g).
[625] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.53-7.34 (2H, m), 7.25-7.20 (2H, m), 4.91 (1H, d, J = 4.6 Hz), 4.81 (2H, s) , 4.31 (1H, dd, J = 4.7, 6.5 Hz), 1.20-1.10 (1H, m), 0.91 (9H, s), 0.47-0.23 (4H, m), 0.10 (3H, s), 0.08 (3H , s).
[626] MS (APCI, m / z) 275 (M + HH ₂ O) ⁺ .
[627] Process 3
[628] (R) -2-[(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methoxymethyl] oxirane
[629]
[630] The title compound (1.04 g) was obtained in the same manner as in Step 2 of Example 1 from (cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methanol (2.11 g) obtained in Step 2.
[631] Process 4
[632] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methoxy] Propane-2-ol
[633]
[634] From (R) -2-[(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methoxymethyl] oxirane (546 mg) obtained in step 3 in the same manner as in step 13 of Example 1 The title compound (345 mg) was obtained.
[635] Process 5
[636] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) [2- (hydroxymethyl) phenyl] methoxy] propane-2- Come
[637]
[638] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl obtained in step 4 ] Methoxy] propan-2-ol (365 mg) was dissolved in tetrahydrofuran (4 mL), and tetrabutylammonium fluoride-1M tetrahydrofuran solution (0.73 mL) was added under ice cooling for 4 hours at room temperature. Stirred. Saturated aqueous ammonium chloride solution (1 ml) was added to the reaction solution, poured into water, and extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order, dried over anhydrous sodium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (ethyl acetate: methanol = 98: 2) to obtain the title compound (221 mg). .
[639] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.90-7.70 (3H, m), 7.67 (1H, s), 7.50-7.20 (7H, m), 5.13 (1H, brs), 4.90-4.40 ( 3H, m), 4.20-4.05 (1H, m), 3.70-3.50 (1H, m), 3.30-3.10 (2H, m), 2.80-2.50 (4H, m), 1.40-0.85 (7H, m), 0.60-0.10 (4H, m).
[640] MS (APCI, m / z) 434 (M + H) ⁺ .
[641] Example 58
[642] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) [2- (hydroxymethyl) phenyl] methoxy] Propane-2-ol hemifumalate
[643] Process 1
[644] 2-tert-butyldimethylsilyloxymethyl-N-methoxy-N-methylbenzamide
[645]
[646] N, O-dimethylhydroxylamine hydrochloride (58.5 g) and ammonium chloride (40.0 g) were sequentially added to a methylene chloride (600 mL) solution of phthalide (26.8 g) under ice cooling, followed by triethylamine (139 mL). ) Was added dropwise for 40 minutes, and stirred at room temperature for 12 hours. The reaction solution was poured into diluted hydrochloric acid, and the organic layer was washed with water and saturated brine in that order, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2-hydroxymethyl-N-methoxy-N-methylbenzamide. The obtained 2-hydroxymethyl-N-methoxy-N-methylbenzamide was dissolved in N, N-dimethylformamide (300 mL), imidazole (9.53 g) and tert-butyldimethylchlorosilane (21.1 g) Was added and stirred at room temperature for 3.5 hours. The reaction solution was poured into water, and extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order, dried over anhydrous sodium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (ethyl acetate: hexane = 1: 3) to obtain the title compound (42.0 g). .
[647] Process 2
[648] (Cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methane
[649]
[650] The title compound (18.4g) was obtained from the 2-tert-butyldimethylsilyloxymethyl-N-methoxy-N-methylbenzamide (21.7 g) obtained in Step 1 in the same manner as in Step 2 of Example 23.
[651] ¹ H-NMR (300 MHz, δ ppm, CDCl ₃ ) 7.88 (1H, dd, J = 1.1,7.7 Hz), 7.78 (1H, d, J = 7.3 Hz), 7.53 (1H, dt, J = 1.2,7.6 Hz ), 7.35 (1H, t, J = 7.2 Hz), 4.97 (2H, s), 2.57-2.48 (1H, m), 1.24-1.20 (2H, m), 1.06-1.01 (2H, m), 0.95 ( 9H, s), 0.11 (6H, s).
[652] Process 3
[653] (R)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methanol
[654]
[655] Dichloro [(S) -2,2'-bis (diphenylphosphino) -1,1'-binafyl] [(S) -1,1'-bis (p-methoxyphenyl) -2-iso (Cyclopropyl) [2- (tert) obtained in step 2 to an isopropanol (100 mL) suspension of propylethane-1,2-diamine] ruthenium (II) (111 mg) and potassium-tert-butoxide (44.9 mg). -Butyldimethylsilyloxymethyl) phenyl] methane (5.81 g) was added and medium pressure hydrogenation (5.0 kgf / cm 2) was carried out at room temperature for 36 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate: hexane = 1: 5) to obtain the title compound (5.82 g).
[656] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.49-7.46 (1H, m), 7.39-7.37 (1H, m), 7.25-7.22 (2H, m), 4.99 (1H, br s), 4.81 (2H, s), 4.32 (1H, d, J = 6.3 Hz), 1,32-1.09 (1H, m), 0.91 (9H, s), 0.49-0.22 (4H, m), 0.10 (3H, s ), 0.08 (3H, s).
[657] MS (ESI, m / z) 275 (M + HH ₂ O) ⁺ .
[658] Process 4
[659] (R) -2-[(1R)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methoxymethyl] oxirane
[660]
[661] The title compound (2.52g) was obtained by the same method as Step 2 of Example 1 from (R)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methanol (2.92g) obtained in Step 3. .
[662] Process 5
[663] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl ] Methoxy] propan-2-ol
[664]
[665] Process 13 of Example 1 from (R) -2-[(1R)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methoxymethyl] oxirane (1.22 g) obtained in step 4 In the same manner as the title compound (1.79g) was obtained.
[666] Process 6
[667] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) [2- (hydroxymethyl) phenyl] methoxy] Propane-2-ol
[668]
[669] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) [2- (tert-butyldimethylsilyl) obtained in step 5 The title compound (710 mg) was obtained in the same manner as in Step 5 of Example 57 from oxymethyl) phenyl] methoxy] propan-2-ol (1.70 g).
[670] Process 7
[671] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) [2- (hydroxymethyl) phenyl] methoxy] Propane-2-ol hemifumalate
[672]
[673] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1R)-(cyclopropyl) [2- (hydroxymethyl) phenyl obtained in step 6 ] Methoxy] propan-2-ol (700 mg) was dissolved in methanol (15 mL), and fumaric acid (94 mg) was added and stirred for 30 minutes. The reaction solution was concentrated under reduced pressure, ether was added to the residue, and the precipitated solid was filtered to obtain the title compound (720 mg).
[674] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.95-7.85 (3H, m), 7.73 (1H, s), 7.55-7.20 (7H, m), 6.51 (1H, s), 4.63 (1H, d, J = 13.2 Hz), 4.56 (1H, d, J = 13.2 Hz), 4.13 (1H, d, J = 7.5 Hz), 3.90-3.80 (1H, brs), 3.40-3.15 (2H, m), 3.05-2.95 (3H, m), 2.80-2.65 (1H, m), 1.20-1.00 (7H, m), 0.60-0.20 (4H, m).
[675] MS (ESI, m / z) 434 (M + H-l / 2C ₄ H ₄ O ₄ ) ⁺ .
[676] Example 59
[677] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1S)-(cyclopropyl) [2- (hydroxymethyl) phenyl] methoxy] Propane-2-ol hemifumalate
[678] Process 1
[679] (S)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methanol
[680]
[681] Dichloro [(R) -2,2'-bis (diphenylphosphino) -1,1'-binafyl] [(R) -1,1'-bis (p-methoxyphenyl) -2-iso (Cyclopropyl) obtained in step 2 of Example 58 in an isopropanol (100 mL) suspension of propylethane-1,2-diamine] ruthenium (II) (111 mg) and potassium-tert-butoxide (44.9 mg) [ 2- (tert-butyldimethylsilyloxymethyl) phenyl] methane (5.81 g) was added to hydrogen (5.0 kgf / cm 2) at medium pressure for 36 hours at room temperature. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate: hexane = 1: 5) to obtain the title compound (5.50 g).
[682] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.49-7.46 (1H, m), 7.40-7.37 (1H, m), 7.22-7.20 (2H, m), 4.99 (1H, d, J = 4.2 Hz), 4.81 (2H, s), 4.31 (1H, dd, J = 4.5, 6.6 Hz), 1.20-1.09 (1H, m), 0.91 (9H, s), 0.47-0.21 (4H, m), 0.10 (3H, s), 0.08 (3H, s).
[683] MS (ESI, m / z) 275 (M + HH ₂ O) ⁺ .
[684] Process 2
[685] (R) -2-[(1S)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methoxymethyl] oxirane
[686]
[687] The title compound (2.62g) was obtained by the same method as Step 2 of Example 1 from (S)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methanol (2.92g) obtained in Step 1. .
[688] Process 3
[689] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1S)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl ] Methoxy] propan-2-ol
[690]
[691] Process 13 of Example 1 from (R) -2-[(1S)-(cyclopropyl) [2- (tert-butyldimethylsilyloxymethyl) phenyl] methoxymethyl] oxirane (1.22 g) obtained in step 2 In the same manner as the title compound (1.80g) was obtained.
[692] Process 4
[693] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1S)-(cyclopropyl) [2- (hydroxymethyl) phenyl] methoxy] Propane-2-ol
[694]
[695] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1S)-(cyclopropyl) [2- (tert-butyldimethylsilyl obtained in step 3 The title compound (1.26g) was obtained from oxymethyl) phenyl] methoxy] propan-2-ol (1.70g) in the same manner as in Step 5 of Example 57.
[696] Process 5
[697] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1S)-(cyclopropyl) [2- (hydroxymethyl) phenyl] methoxy] Propane-2-ol hemifumalate
[698]
[699] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(1S)-(cyclopropyl) [2- (hydroxymethyl) phenyl obtained in step 4 The title compound (1.33 g) was obtained in the same manner as in Step 7 of Example 58 from] methoxy] propan-2-ol (1.25 g).
[700] ¹ H-NMR (300 MHz, δ ppm, DMSO-d ₆ ) 7.90-7.80 (3H, m), 7.71 (1H, s), 7.50-7.20 (7H, m), 6.48 (1H, s), 4.63 (1H, d, J = 13.2 Hz), 4.56 (1H, d, J = 13.2 Hz), 4.12 (1H, d, J = 7.8 Hz), 3.80-3.70 (1H, brs), 3.35-3.15 (2H, m), 2.95-2.85 (3H, m), 2.80-2.65 (1H, m), 1.20-1.00 (7H, m), 0.60-0.20 (4H, m).
[701] MS (ESI, m / z) 434 (M + H-l / 2C ₄ H ₄ O ₄ ) ⁺ .
[702] Example 60- Example 160
[703] In the same manner as in Examples 1 to 59, the compounds of Examples 60 to 160 were obtained. These are shown to Tables 8-23.
[704] TABLE 8
[705]
[706]
[707] TABLE 9
[708]
[709]
[710] TABLE 10
[711]
[712]
[713] TABLE 11
[714]
[715]
[716] TABLE 12
[717]
[718]
[719] TABLE 13
[720]
[721]
[722] TABLE 14
[723]
[724]
[725] TABLE 15
[726]
[727]
[728] TABLE 16
[729]
[730]
[731] TABLE 17
[732]
[733]
[734] TABLE 18
[735]
[736]
[737] TABLE 19
[738]
[739]
[740] TABLE 20
[741]
[742]
[743] TABLE 21
[744]
[745]
[746] Table 22
[747]
[748]
[749] TABLE 23
[750]
[751] [Test Example]
[752] Next, the biological activity of the compounds of the present invention was tested.
[753] Test Example 1
[754] Assessment of antagonism of calcium receptors using reporter genes
[755] Cultured overnight in a medium (F12 medium containing 0.5% dialyzed horse serum and 0.25% dialysate fetal serum) using transformed cells incorporating luciferase cDNA and human calcium receptor cDNA into a rat adrenal derived cell line It was. The next day, to the test compound group, a 10-fold dilution of a dimethyl sulfoxide solution containing 0.01 to 100 mM of the test compound in the medium was added to 10 µl per well. 10 μl of 50 mM calcium chloride-containing medium was added to the control group so that the calcium concentration in the medium was 5 mM. Only medium was added to the blank group. After incubation for 4 hours, luciferase substrate (PicaGene LT-2.0, Toyo Ink) was added, and luciferase activity was measured by photoluminometer. Inhibition rate (%) was calculated | required by the following formula from the obtained measured value.
[756] % Inhibition = 100-{(Measured value of compound group-measured value of blank group) / (Measured value of control group-measured value of blank group)} × 100
[757] Based on the above results, a concentration (IC ₅₀ ) showing 50% inhibition was determined.
[758] In the above formula [I-3], R ¹¹ , R ¹² and R ²¹ are hydrogen atoms, and R ⁷¹ and R ⁷² are united to represent -CH = CH-CH = CH-.
[759]
[760] It tested for reference also about (Comparative example 1). The results are shown in Table 24 and Table 25.
[761] Test Example 2
[762] PTH secretion promoting action
[763] In 6-9 week-old male SD rats (CHARLES RIVER JAPAN, INC.) Fasted for 20 hours, the test compound was treated with 30 mg / 5 ml / kg and 100 mg using a solvent (5% ethanol, 0.5% methylcellulose solution). Oral administration at a dose of 5 ml / kg. The control group was orally administered with only 5 ml / kg of solvent. Immediately before administration of the test compound and 0.5, 1, 2, 4, 6 hours after administration, blood was collected from the tail vein to collect serum. PTH concentration in serum was measured with rat PTH (1-84) ELISA kit (Nohon Medi-Physics Co., Ltd.). Results of PTH concentration in serum before administration, 30 minutes after administration and 4 hours after administration are shown in Table 24, and the serum PTH concentration before administration, 30 minutes after administration and 2 hours after administration of the 30 mg / 5 ml / kg dose group. The results are shown in Table 25.
[764] 1, 2 and 3 show changes over time of serum PTH concentrations at the doses (30 mg / kg) of Examples 22, 23 and 24. For reference, FIG. 4 shows the change over time of the serum PTH concentration at the dose of Comparative Example 1 (100 mg / kg), and FIG. 5 at the dose of NPS-2143 (30 mg / kg). The change in serum PTH concentration over time is shown.
[765] Test compoundIC ₅₀ (μM)PTH concentration in serum (pg / ml) Before dosing30 minutes laterAfter 240 minutes 30mg / kg administration group (upper) 100mg / kg administration group (bottom) Example 10.04156.9 ± 9.4141.5 ± 15.354.1 ± 7.7 55.8 ± 3.9160.0 ± 13.858.3 ± 7.3 Example 20.02752.0 ± 3.4148.4 ± 10.160.6 ± 5.8 68.9 ± 7.6154.8 ± 17.185.8 ± 17.3 Example 50.07078.9 ± 11.8155.6 ± 14.984.8 ± 12.3 --- Example 220.05962.5 ± 5.2185.7 ± 10.073.4 ± 11.0 --- Example 230.02785.3 ± 3.6228.3 ± 15.073.9 ± 6.9 --- Example 240.02266.5 ± 4.3197.7 ± 18.977.5 ± 9.0 --- Example 620.04599.3 ± 43.6259.2 ± 29.482.2 ± 9.9 --- Comparative Example 10.56--- 107.1 ± 17.5139.0 ± 18.878.9 ± 12.3 -Is not measured, mean ± standard error
[766] Test compoundIC ₅₀ (μM)PTH concentration in serum (pg / ml) Before dosing30 minutes later120 minutes later Example 800.06444.8 ± 6.3156.6 ± 15.376.1 ± 12.6 Example 820.05166.7 ± 5.0121.9 ± 9.068.5 ± 11.4 Example 950.029105.8 ± 44.2199.1 ± 25.880.4 ± 9.6 Example 1000.06752.2 ± 4.4130.1 ± 53.749.3 ± 4.4 Example 1050.04938.3 ± 8.6115.4 ± 20.074.3 ± 12.1 Example 1110.02451.2 ± 12.8236.3 ± 60.865.3 ± 6.4 Example 1270.13365.0 ± 6.9265.3 ± 22.375.2 ± 7.3 -Is not measured, mean ± standard error
[767] Test Example 3
[768] PTH secretion promoting action
[769] The test compound was orally administered at 30 mg / 5 ml / kg using a solvent (5% ethanol, 0.5% methylcellulose solution) to 4-6 week-old female Fischer rats fasted for 20 hours. It was. The control group was orally administered with only 5 ml / kg of solvent. Immediately before administration of the test compound and 0.5, 1, 2, 4 hours after administration, blood was collected from the tail vein to collect serum. PTH concentration in serum was measured with rat PTH (1-84) ELISA kit (Nohon Medi-Physics Co., Ltd.). Table 26 shows the results of PTH concentration in serum before administration, 30 minutes after administration and 4 hours after administration.
[770] Test compoundPTH concentration in serum (pg / ml) Before dosing30 minutes laterAfter 240 minutes Example 58179.2 ± 45.6644.4 ± 65.2394.1 ± 100.9 Example 59189.8 ± 90.9313.4 ± 103.362.2 ± 10.3 Example 6282.9 ± 14.5620.6 ± 34.2100.1 ± 11.7 Mean ± Standard Error
[771] In order to treat osteoporosis by increasing the blood concentration of PTH by inhibiting the action of calcium receptors, the compound used herein should have at least the following characteristics.
[772] (i) This compound has sufficient antagonism against calcium receptors. That is, the compound has a sufficiently low IC ₅₀ value. Incidentally, in WO99 / 51241, "In general, compounds having low IC ₅₀ values in assays of inhibitors of calcium receptors are better compounds. Compounds having IC ₅₀ values of ₅₀ μM or more are considered inert. Preferred compounds are 10 μM or less Has an IC ₅₀ value, more preferably has an IC ₅₀ value of 1 μM or less, and most preferably has an IC ₅₀ value of 0.1 μM or less.
[773] (ii) By administering this compound, the blood PTH concentration is sufficiently improved.
[774] (iii) Blood levels are not persistent over time when this compound is administered. Preferably, 3, 4 hours after administration of this compound, the concentration is returned to the PTH concentration before administration.
[775] From the above test results, it is clear that the compound of the present invention has the above characteristics.
[776] for (i); As described in Table 24 and Table 25, the IC ₅₀ values of the compounds of the present invention are all 1 μM or less, which has sufficient antagonism against calcium receptors. The compounds of the present invention are all preferred compounds in view of IC ₅₀ values.
[777] As shown in Tables 24 to 26 and Figs. 1 to 3 for (ii), 2.0 to 3.0 times before administration in the 30 mg / kg administration group and 30 to 2.2 times before administration in the 100 mg / kg administration group after 30 minutes. There was a blood PTH concentration, and it was confirmed that all compounds of the present invention had excellent PTH secretion promoting action. On the other hand, as shown in Table 24 and FIG. 4, the compound of Comparative Example 1 had only 1.3-fold blood PTH concentration 30 minutes after administration even at a 100 mg / kg dose, and thus excellent PTH secretion promoting action could not be confirmed, and thus it can be expected as a pharmaceutical. none.
[778] for (iii); As shown in Tables 24 to 26 and FIGS. 1 to 3, the PTH secretion of the compounds of the present invention reached a peak 30 minutes after administration, and then rapidly decreased thereafter, after which the blood PTH concentration before administration was about 2-4 hours. Return to. It can be seen that the compound of the present invention is excellent in this respect. On the other hand, as a result of further testing of NPS-2143 disclosed in the literature, it was confirmed that the PTH secretion promoting action of NPS-2143 was sustained (in FIG.
[779] The compound represented by the formula [I] according to the present invention has excellent calcium receptor antagonism, as can be seen also in Test Example 1. Thus, therapeutic drugs such as diseases involving abnormalities of calcium homeostasis, such as osteoporosis, epithelial hypogonadism, osteosarcoma, periodontal disease, osteoporosis, osteoarthritis, chronic arthritis, chronic arthritis, Paget's disease, liquid hypercalcemia, autosomal dominant hypocalcemia As a usefulness is expected. In addition, as can be seen from Test Examples 2 and 3, the compound of the present invention has a temporary PTH secretion promoting action. Therefore, it is especially useful as a medicine for treating osteoporosis.
[780] This application is based on Japanese Patent Application Nos. 2000-244536 and 2001-132879 filed in Japan, the contents of which are all incorporated herein.

权利要求:
Claims (21)
[1" claim-type="Currently amended] A compound represented by the formula [I], a salt thereof, a solvate thereof, or a prodrug thereof:
[Formula I]
[Wherein, R ¹ is an aryl group or a heteroaryl group (this aryl group and heteroaryl group is a halogen atom, a C _1-6 alkyl group, a halo (C _1-6 ) alkyl group, a hydroxy (C _1-6 ) alkyl group, C _1-6 alkoxycarbonyl (C _1-6) alkyl group, a hydroxyl group, C _1-6 alkoxy groups, halo (C _1-6) alkoxy group, a mercapto group, C _1-6 alkylthio, C _1-6 alkyl sulfanyl group , C _1-6 alkylsulfonyl group, aminosulfonyl group, C _1-6 alkylsulfamoyl group, di (C _1-6 ) alkylsulfamoyl group, carboxyl group, (C _1-6 alkoxy) carbonyl group, C _1-7 ah Real group, carbamoyl group, (C _1-6 alkyl) carbamoyl group, di (C _1-6 alkyl) carbamoyl group, cyano group, nitro group, amino group, C _1-6 alkylamino group, di (C _1-6 ) Alkylamino group, C _1-7 acylamino group, C _1-3 alkylenedioxy group,

It may be substituted with 1 to 3 substituents selected from (wherein R ^A is (C _1-6 alkoxy) represents a carbonyl group or carboxyl group, R ^B represents a hydrogen atom or a C _1-6 alkyl group)} represents;
R ² is a C _1-6 alkyl group (this C _1-6 alkyl group is a halogen atom, hydroxyl group, C _1-6 alkoxy group, carboxyl group, amino group, C _1-6 alkylamino group, di (C _1-6 ) alkylamino group and oxo It may be substituted with 1 to 3 substituents selected from the group), C _3-7 cycloalkyl group, C _2-6 alkenyl group, C _2-6 alkynyl group, aralkyl group, carboxyl group, (C _1-6 alkoxy) carbonyl group Or a cyano group;
R ³ is a hydrogen atom, C _1-6 alkyl group, hydroxyl group, C _1-6 alkoxy group, mercapto group, C _1-6 alkylthio group, carboxyl group, (C _1-6 alkoxy) carbonyl group, (C _1-6 alkyl ) Carbamoyl group, di (C _1-6 alkyl) carbamoyl group, amino group, C _1-6 alkylamino group or di (C _1-6 ) alkylamino group;
R ⁴ represents a hydrogen atom, a C _1-6 alkyl group or a C _2-6 alkenyl group, or R ³ and R ⁴ are monovalent to represent an oxo group;
R ⁵ and R ⁶ are the same or different, each represent a C _1-6 alkyl group, or R ⁵ and R ⁶ are integrated to represent a cyclopropyl group together with the carbon atom to which they are bonded;
R ⁷ is an aryl group or heteroaryl group (This aryl group and heteroaryl group is a halogen atom, C _1-6 alkyl group, halo (C _1-6 ) alkyl group, hydroxy (C _1-6 ) alkyl group, C _3-7 cyclo Alkyl group, hydroxyl group, C _1-6 alkoxy group, halo (C _1-6 ) alkoxy group, carboxyl group, (C _1-6 alkoxy) carbonyl group, nitro group, cyano group, C _1-6 alkylsulfonyloxy group, carbamoyl group And may be substituted with 1 to 3 substituents selected from C _1-3 alkylenedioxy groups.
X ¹ represents a single bond, a C _1-6 alkylene group or a C _2-6 alkynylene group (this C _1-6 alkylene group and C _2-6 alkynylene group may be substituted with a C _1-6 alkyl group or an oxo group) Represents;
X ² represents a C _1-6 alkylene group (this C _1-6 alkylene group may be substituted with a C _1-6 alkyl group or a halo (C _1-6 ) alkyl group);
X ³ represents a single bond or a C _1-6 alkylene group (this C _1-6 alkylene group may be substituted with a hydroxyl group or an oxo group);
X ⁴ and X ⁵ are united to form a single bond, methylene group, -NH-, oxygen atom, sulfur atom, -C (= O)-, -CH ₂ NH-, -CH ₂ O-, -CH ₂ S-, _{-CH 2 CO-, -NHCH 2 -,} -OCH 2 -, -SCH 2 -, -COCH 2 -, represents a -CH = CH- or -C≡C-].
[2" claim-type="Currently amended] A compound represented by the formula [I '], a salt thereof, a solvate thereof, or a prodrug thereof:
[Formula I ']
[Wherein, R ^{1 ′} is an aryl group or a heteroaryl group (this aryl group and heteroaryl group is a halogen atom, a C _1-6 alkyl group, a halo (C _1-6 ) alkyl group, a hydroxy (C _1-6 ) alkyl group, C _1-6 alkoxy (C _1-6) alkyl group, a hydroxyl group, C _1-6 alkoxy groups, halo (C _1-6) alkoxy group, a mercapto group, C _1-6 alkylthio, C _1-6 alkyl sulfanyl Nyl group, C _1-6 alkylsulfonyl group, aminosulfonyl group, C _1-6 alkylsulfamoyl group, di (C _1-6 ) alkylsulfamoyl group, carboxyl group, (C _1-6 alkoxy) carbonyl group, C _1-7 Acyl group, carbamoyl group, (C _1-6 alkyl) carbamoyl group, di (C _1-6 alkyl) carbamoyl group, cyano group, nitro group, amino group, C _1-6 alkylamino group, di (C _{1- 6} ) may be substituted with 1 to 3 substituents selected from an alkylamino group and a C _1-7 acylamino group;
R ^{7 '} is an aryl group or heteroaryl group (This aryl group and heteroaryl group are halogen atoms, C _1-6 alkyl group, halo (C _1-6 ) alkyl group, C _3-6 cycloalkyl group, hydroxyl group, C _1-6 alkoxy It may be substituted with 1 to 3 substituents selected from the group, halo (C _1-6 ) alkoxy group, carboxyl group, (C _1-6 alkoxy) carbonyl group, nitro group, cyano group and C _1-6 alkylsulfonyloxy group. };
R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , X ¹ , X ² , X ³ , X ⁴ and X ⁵ are the same as in paragraph 1, respectively.
[3" claim-type="Currently amended] A compound represented by the formula [I ″], a salt thereof, or a solvate thereof or a prodrug thereof:
[Formula I ”]
[Wherein, R ^{1 ″} represents an aryl group or a heteroaryl group (this aryl group and heteroaryl group are C _1-3 alkylenedioxy group,

(Wherein R ^A represents a (C _1-6 alkoxy) carbonyl group or a carboxy group, R ^B represents a hydrogen atom or a C _1-6 alkyl group).
R ^{7 "} is an aryl group or heteroaryl group (this aryl group and heteroaryl group may be substituted with 1 to 3 substituents selected from hydroxy (C _1-6 ) alkyl group, carbamoyl group and C _1-3 alkylenedioxy May be used;
R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , X ¹ , X ² , X ³ , X ⁴ and X ⁵ are the same as in paragraph 1, respectively.
[4" claim-type="Currently amended] Compounds represented by the formula [I-2], salts thereof or solvates thereof or prodrugs thereof:
[Formula I-2]
[Wherein, R ¹¹ and R ¹² are the same or different and each is a hydrogen atom, a halogen atom, a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, A hydroxyl group, a C _1-4 alkoxy group, a cyano group, or a nitro group, or R ¹¹ and R ¹² are integrated to represent a C _1-3 alkylenedioxy group, and R ²¹ is a C _1-4 alkyl group (this alkyl group is C _May be substituted with a _1-4 alkoxy group), a C _3-5 cycloalkyl group, a C _2-4 alkenyl group or an aralkyl group, and R ³ , R ⁴ , R ⁵ , R ⁶ , R ⁷ , X ¹ , X ² , X ³ , X ⁴ and X ⁵ are the same as in Claim 1].
[5" claim-type="Currently amended] The compound represented by the formula [I-3], a salt thereof, or a solvate thereof, or a prodrug thereof according to claim 4;
[Formula I-3]
Wherein R ⁷¹ and R ⁷² are the same or different and each represents a hydrogen atom, a C _1-4 alkyl group or a C _1-4 alkoxy group, or are integral with -CH = CH-CH = CH- or C _1-3 An alkylenedioxy group, and R ¹¹ , R ¹² and R ²¹ are the same as in Claim 4).
[6" claim-type="Currently amended] 6. A compound according to claim 5, wherein R ¹¹ and R ¹² are the same or different and each represents a hydrogen atom, a chlorine atom, a methyl group, a hydroxymethyl group, a hydroxyl group, a methoxy group, a cyano group or a nitro group, or R ¹¹ and R ¹² are integral Wherein m ²¹ represents a methylenedioxy group and R ²¹ is a C _1-4 alkyl group or C _3-5 cycloalkyl group which may be branched, salts thereof, or solvates thereof or prodrugs thereof.
[7" claim-type="Currently amended] 7. A compound, a salt thereof, or a solvate thereof, or a prodrug thereof, according to claim 6, wherein R ²¹ is a methyl group, an ethyl group, a cyclopropyl group, or a cyclobutyl group.
[8" claim-type="Currently amended] 8. A compound according to claim 7, wherein R ¹¹ is a hydrogen atom, R ¹² is a methyl group, a methoxy group or a hydroxymethyl group, or R ¹¹ and R ¹² are united to represent a methylenedioxy group, and R ²¹ is a methyl group or a cyclopropyl group Compounds, salts thereof or solvates thereof or prodrugs thereof.
[9" claim-type="Currently amended] 9. A compound, a salt thereof, or a solvate thereof, or a prodrug thereof, according to claim 8, wherein R ²¹ is a cyclopropyl group.
[10" claim-type="Currently amended] 10. A compound, a salt thereof, or a solvate thereof, or a prodrug thereof, according to claim 9, wherein R ⁷¹ and R ⁷² are united to represent -CH = CH-CH = CH-.
[11" claim-type="Currently amended] The compound, salt thereof or solvate thereof or prodrug thereof according to claim 9, wherein R ⁷¹ and R ⁷² are selected from C _1-4 alkyl groups and C _1-4 alkoxy groups.
[12" claim-type="Currently amended] The compound of claim 1, wherein the compound is (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methoxyphenyl) methoxy ] Propan-2-ol,
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-methylphenyl) methoxy] propan-2-ol,
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (phenyl) methoxy] propan-2-ol,
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) ethoxy] propan-2-ol,
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methylphenyl) ethoxy] propan-2-ol,
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-methoxyphenyl) propoxy] propan-2-ol,
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (2-cyanophenyl) ethoxy] propan-2-ol,
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (3-methoxyphenyl) ethoxy] propan-2-ol and
(2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3- [1- (3-methylphenyl) ethoxy] propan-2-ol, the compound Salts or solvates thereof or prodrugs thereof.
[13" claim-type="Currently amended] (2R) -1- [1,1-dimethyl-2- (naphthalen-2-yl) ethylamino] -3-[(cyclopropyl) (2-hydroxymethylphenyl) methoxy] propan-2-ol, its Salts or solvates thereof or prodrugs thereof.
[14" claim-type="Currently amended] A pharmaceutical composition comprising the compound according to any one of claims 1 to 13, a salt thereof, a solvate thereof, or a prodrug thereof as an active ingredient.
[15" claim-type="Currently amended] A calcium receptor antagonist comprising the compound according to any one of claims 1 to 13, a salt thereof, a solvate thereof, or a prodrug thereof as an active ingredient.
[16" claim-type="Currently amended] A therapeutic agent for osteoporosis, comprising the compound according to any one of claims 1 to 13, a salt thereof, a solvate thereof, or a prodrug thereof as an active ingredient.
[17" claim-type="Currently amended] Compound represented by general formula [II] or its salt or solvate:
[Formula II]
[Wherein, R ^{11 ′} is a halogen atom, a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, a hydroxyl group, a C _1-4 alkoxy group, tert -Butyldimethylsilyloxymethyl group, cyano group or nitro group].
[18" claim-type="Currently amended] 18. A compound according to claim 17, or a salt or solvate thereof, wherein R ^{11 '} in the formula [II] is a C _1-4 alkyl group, a hydroxy (C _1-6 ) alkyl group or a C _1-4 alkoxy group.
[19" claim-type="Currently amended] Compound represented by general formula [III], its salt, or solvate:
[Formula III]
[Wherein, R ^{11 ″} is a halogen atom, a hydroxy (C _1-6 ) alkyl group, a C _1-6 alkoxy (C _1-6 ) alkyl group, a hydroxyl group, a C _1-4 alkoxy group, tert-butyldimethylsilyloxymethyl group , Cyano group or nitro group].
[20" claim-type="Currently amended] 20. A compound according to claim 19, or a salt or solvate thereof, wherein in Formula [III], R ^{11 "} is a C _1-4 alkoxy group.
[21" claim-type="Currently amended] Compound represented by general formula [IV], its salt, or its solvate:
[Formula IV]
[Wherein, R ⁸ represents a carboxy group, nitro group, tert-butoxycarbonylamino group or benzyloxycarbonylamino group].

类似技术:

---

公开号 | 公开日 | 专利标题

---

US6525036B2|2003-02-25|Compounds and compositions as protease inhibitors

---

US6017919A|2000-01-25|Compounds and pharmaceutical use thereof

---

US6476026B1|2002-11-05|Compounds and compositions as protease inhibitors

---

NL1031976C2|2007-04-17|N- | sulfonamide derivatives.

---

DE60219595T2|2008-01-10|Method for treating diseases with malonyl coa decarboxylase inhibitors

---

EP1373233B1|2007-09-05|Derivatives of n-|beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same

---

KR0128289B1|1998-04-02|1-biphenylmethylimidazole derivatives their preparation and their therapeutic use

---

EP1284963B1|2012-05-09|Novel calcium receptor active molecules and method for preparing same

---

US4554371A|1985-11-19|Phenoxyalkylcarboxylic acids

---

US8273745B2|2012-09-25|Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents

---

RU2247579C2|2005-03-10|Combined treatment using benzothiepins inhibiting transport of bile acid in jejunum and inhibitors of hmg-coa-reductase

---

JP4346113B2|2009-10-21|Arylsulfonamides and their analogs and their use in the treatment of neurodegenerative diseases

---

DE69736007T2|2006-12-28|Preventing loss and restoring bone mass using prostaglandin analogs

---

KR100389497B1|2003-09-19|Amino | ether derivatives

---

AU779610B2|2005-02-03|Cyclic amine CCR3 antagonists

---

ES2287739T3|2007-12-16|Matrix metaloproteinase inhibitors.

---

CA2748251C|2016-08-02|Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor

---

ES2233700T3|2005-06-16|Derivatives of aminopropoxiaril substitutes useful as agonists for lxr

---

KR101589332B1|2016-01-27|2h-chromene compound and derivative thereof

---

EP0543858B1|2000-12-20|Benzimidazole derivatives, process for their preparation and application

---

EP0597088B1|2000-12-06|Novel imidazole derivatives, their preparation and therapeutic applications

---

FI95027B|1995-08-31|Process for the preparation of therapeutically useful 3-substituted pyrrolidine derivatives

---

EP0675118B1|2002-10-09|Biphenylderivatives, process for their preparation and their use as medicaments

---

JP2007525482A|2007-09-06|Amide compounds and their use as ion channel ligands

---

US20050038035A1|2005-02-17|Heterocyclic amide compounds as apolipoprotein b inhibitors

同族专利:

---

公开号 | 公开日

---

AU7775201A|2002-02-25|

---

US20040006130A1|2004-01-08|

---

US6916956B2|2005-07-12|

---

US7211685B2|2007-05-01|

---

WO2002014259A1|2002-02-21|

---

CA2418794A1|2003-02-10|

---

DE60136187D1|2008-11-27|

---

EP1308436A4|2005-10-05|

---

KR100785675B1|2007-12-14|

---

AT411275T|2008-10-15|

---

EP1308436B1|2008-10-15|

---

EP1308436A1|2003-05-07|

---

CA2418794C|2009-11-24|

---

US20050107448A1|2005-05-19|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2000-08-11|Priority to JPJP-P-2000-00244536

---

2000-08-11|Priority to JP2000244536

---

2001-04-27|Priority to JP2001132879

---

2001-04-27|Priority to JPJP-P-2001-00132879

---

2001-08-10|Application filed by 니뽄 다바코 산교 가부시키가이샤

---

2001-08-10|Priority to PCT/JP2001/006903

---

2003-07-07|Publication of KR20030059100A

---

2007-12-14|Application granted

---

2007-12-14|Publication of KR100785675B1

优先权:

---

申请号 | 申请日 | 专利标题

---

JPJP-P-2000-00244536|2000-08-11|

---

JP2000244536|2000-08-11|

---

JP2001132879|2001-04-27|

---

JPJP-P-2001-00132879|2001-04-27|

---

PCT/JP2001/006903|WO2002014259A1|2000-08-11|2001-08-10|Calcium receptor antagonists|